<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Immune globulin (Intravenous, subcutaneous, and intramuscular): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Immune globulin (Intravenous, subcutaneous, and intramuscular): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Immune globulin (Intravenous, subcutaneous, and intramuscular): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="16471" href="/d/html/16471.html" rel="external">see "Immune globulin (Intravenous, subcutaneous, and intramuscular): Drug information"</a> and <a class="drug drug_patient" data-topicid="16472" href="/d/html/16472.html" rel="external">see "Immune globulin (Intravenous, subcutaneous, and intramuscular): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F54987185"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Expiration Date Extension for Asceniv</span>
<span class="collapsible-date">June 2022</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA has approved an extension of the expiration date of ADMA Biologics' Asceniv (immune globulin) 10% liquid from 24 to 36 months when stored at 2 to 8°C (36 to 46°F). The new expiration date is valid for 6 Asceniv lots that were manufactured and distributed in 2019 and 2020. Future lots will be labeled according to the new dating period.</p>
<p style="text-indent:0em;">Further information, including the impacted lots, may be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fvaccines-blood-biologics%2Fsafety-availability-biologics%2Fexpiration-date-extension-6-asceniv-immune-globulin-intravenous-human-slra-10-liquid-lots&amp;token=%2BvJzIl4sDLDVuqpfv2hdsH%2FW5oU%2Fu%2BKjDioN4szYIJ3neQ9rFeiSL3f3eD1LEDAk8e7LOhTkKkuNmf6NOF0uLpPiuBT4vKrTA1JX4EywPpuOuh7LvkATKwVQjGbJfP9C8Qb1iNm8hyLCV9EomWzM0Ii8TzfW0uvXvYCnadYdKzA%3D&amp;TOPIC_ID=83878" target="_blank">https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/expiration-date-extension-6-asceniv-immune-globulin-intravenous-human-slra-10-liquid-lots</a>.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Expiration Date Extension for Bivigam</span>
<span class="collapsible-date">May 2022</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA has approved an extension of the expiration date of ADMA Biologics’ Bivigam (immune globulin) intravenous liquid 10% from 24 to 36 months when stored at 2 to 8°C (36 to 46°F). The new expiration date is valid for 120 Bivigam lots that were manufactured and distributed in 2020 to 2022. Future lots will be labeled according to the new dating period.</p>
<p style="text-indent:0em;">Further information, including the impacted lots, may be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fvaccines-blood-biologics%2Fsafety-availability-biologics%2Fexpiration-date-extension-120-bivigam-immune-globulin-intravenous-human-10-liquid-lots-manufactured&amp;token=n%2BRbdbCWrV0YN7thYtHWFtwUw90o%2Bv4aiZEcIgJKsHtb7L4IEvpEf3Xc0bN9BZL5XZKWsO8eaQYvE%2BvzAr1cuGi%2F%2Ftn93%2BA6BMWcqPc%2Bp4CvEwcWN8Almu00DBkLufxldjqBdbLAvgH30%2B0YN2IZ4vK%2FC0qinwME8rjf4sTjQinyCfYwDkCHhxD3GR9NIJSW&amp;TOPIC_ID=83878" target="_blank">https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/expiration-date-extension-120-bivigam-immune-globulin-intravenous-human-10-liquid-lots-manufactured</a>.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal of Select Immune Globulin Intravenous and Subcutaneous Products</span>
<span class="collapsible-date">March 2022</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA along with manufacturers of affected products have voluntarily withdrawn certain lots of immune globulin intravenous (IGIV) and immune globulin subcutaneous (IGSC) due to a higher rate of allergic/hypersensitivity-type reactions, some clinically significant.</p>
<p style="text-indent:0em;">Further information on affected products and lot numbers is available at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fvaccines-blood-biologics%2Fsafety-availability-biologics%2Fvoluntary-lot-withdrawals-immune-globulin-intravenous-igiv-and-immune-globulin-subcutaneous-igsc&amp;token=BPbApzdFQ04ZmvesRCSFZvH6NIRvL06ATKuc%2BJE%2BMdkD7IioxdhGO6HSlQFxzQBsCdWZlDsxNA4BmieXS7XPQVcDjkEosDjQEGCy6YFH8A1CS0p80hY4sENduUDq%2BKaZCaeHc9o5a9K77o3oYgROEBQ2OTqwPJH%2FAoe%2Bdn%2Fd9t4%3D&amp;TOPIC_ID=83878" target="_blank">https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/voluntary-lot-withdrawals-immune-globulin-intravenous-igiv-and-immune-globulin-subcutaneous-igsc</a></p></div>
</div>
</div>
<div class="block black-box-warn drugH1Div" id="F11513229"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Thrombosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Thrombosis may occur with immune globulin products. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. For patients at risk of thrombosis, administer at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Renal dysfunction and acute renal failure (excluding Cutaquig, Cuvitru, Hizentra, HyQvia, GamaSTAN, and Xembify):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients with immune globulin intravenous (IGIV) products. Patients predisposed to renal dysfunction include those with any degree of preexisting renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. (<b>Note: </b>The following IV products do not contain sucrose: Asceniv, Bivigam, Flebogamma DIF, Gammagard Liquid, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam 5%, Octagam 10%, Panzyga, and Privigen.) For patients at risk of renal dysfunction or acute renal failure, administer IGIV products at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F11513233"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Asceniv;</li>
<li>Bivigam;</li>
<li>Carimune NF [DSC];</li>
<li>Cutaquig;</li>
<li>Cuvitru;</li>
<li>Flebogamma DIF;</li>
<li>GamaSTAN;</li>
<li>Gammagard;</li>
<li>Gammagard S/D Less IgA;</li>
<li>Gammaked;</li>
<li>Gammaplex;</li>
<li>Gamunex-C;</li>
<li>Hizentra;</li>
<li>Hyqvia;</li>
<li>Octagam;</li>
<li>Panzyga;</li>
<li>Privigen;</li>
<li>Xembify</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871250"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cutaquig;</li>
<li>Cuvitru;</li>
<li>Gamastan S/D [DSC];</li>
<li>Gammagard;</li>
<li>Gammagard S/D;</li>
<li>Gamunex;</li>
<li>Hizentra;</li>
<li>Hyqvia;</li>
<li>IGIVnex;</li>
<li>Iveegam Immuno;</li>
<li>Octagam;</li>
<li>Panzyga;</li>
<li>Privigen</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F13307640"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Blood Product Derivative</span>;</li>
<li>
<span class="list-set-name">Immune Globulin</span></li></ul></div>
<div class="block don drugH1Div" id="F53462645"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Not all products are interchangeable with regards to route of administration; consult manufacturers' labeling for additional information. Consider osmolarity and concentration during product selection; infuse as slowly as indication and stability allow (consult "Immune Globulin Product Comparison" for additional details). Dosage expressed as mg/kg or mL/kg dependent upon route of administration; use extra caution to ensure accuracy.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58acdf8a-6a05-45e7-a020-bd4c6e72f2ed">Immune thrombocytopenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Immune thrombocytopenia (ITP):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Acute: Carimune NF 6%, Gammaked, Gamunex C: IV: 400 mg/kg/<b>day</b> for 2 to 5 consecutive days or 1,000 mg/kg/<b>day</b> for 1 to 2 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4db1a994-1ec5-4c51-b5fa-93dc0f09e491">Isoimmune hemolytic disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Isoimmune hemolytic disease (Rh-incompatibility):</b> IV: GA ≥35 weeks: 500 to 1,000 mg/kg/dose once over 2 hours; if needed, dose may be repeated in 12 hours; most effective when administered as soon as possible after diagnosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15231951','lexi-content-ref-18723908','lexi-content-ref-12496219','lexi-content-ref-15590442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15231951','lexi-content-ref-18723908','lexi-content-ref-12496219','lexi-content-ref-15590442'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="01dcbd5b-32d8-484e-8773-8dcf77f39e13">Measles, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Measles, prophylaxis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23760231']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23760231'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Preexposure prophylaxis (eg, during an outbreak, travel to endemic area): Immunocompromised patients: IV: ≥400 mg/kg/dose within 3 weeks before anticipated exposure.</p>
<p style="text-indent:-2em;margin-left:4em;">Postexposure prophylaxis: Any neonate without evidence of measles immunity:</p>
<p style="text-indent:-2em;margin-left:6em;">IM: 0.5 <b>mL</b>/kg/dose within 6 days of exposure. <b>Note:</b> Not all immune globulin preparations may be administered by the IM route; of the products currently available on the market, GamaSTAN may be given IM; consult product labeling for additional information as market availability may change. <b>Note:</b> GamaSTAN manufacturer labeling suggests a lower IM dose; however, this dosing was based on previous immune globulin donor potency concentrations; recent data indicates that potency from current donor populations has decreased (ie, measles immunity now from vaccinations instead of immunity from disease) requiring a higher IM immune globulin dose (0.5 <b>mL</b>/kg) in all patients without evidence of measles immunity to ensure adequate serum titers.</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 400 mg/kg/dose within 6 days of exposure.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c0a8a050-cc71-45aa-bc5d-3cac3c9c461a">Myasthenia gravis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myasthenia gravis (severe exacerbation):</b> IV: 400 to 1,000 mg/kg/dose once daily over 2 to 5 days for a total dose of 2,000 mg/kg; if additional therapy required, dose should be based on clinical response and titrated to minimum effective dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9535308','lexi-content-ref-17397768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9535308','lexi-content-ref-17397768'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7424aa58-c6b5-4af4-90aa-22eccdf87e98">Myocarditis, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myocarditis, acute:</b> IV: 2,000 mg/kg as a single dose. A cohort study of 21 young patients, including neonates, showed improvement in LVF recovery and survival at 1 year as compared to untreated historical cohort (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8281654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8281654'])">Ref</a></span>); efficacy results are variable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15680069','lexi-content-ref-15155409','lexi-content-ref-19936586']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15680069','lexi-content-ref-15155409','lexi-content-ref-19936586'])">Ref</a></span>); the largest data analysis did not show clear clinical benefit nor positive impact on survival (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19936586']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19936586'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c6f6af3d-eec0-4905-b145-7add8192be3d">Sepsis, adjunctive treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sepsis, adjunctive treatment:</b> IV: Limited data available; efficacy results variable: Usual dose: 500 to 1,000 mg/kg/dose once daily for 1 to 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9099759','lexi-content-ref-20238315']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9099759','lexi-content-ref-20238315'])">Ref</a></span>). The largest trial, INIS (n=3,493), reported no difference in outcomes (including incidence of subsequent sepsis, death, or major disability at 2 years) between treatment and control groups using 500 mg/kg/day for 2 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21962214']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21962214'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F11513276"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Not all products are interchangeable with regards to route of administration; consult manufacturers' labeling for additional information. Consider osmolarity and concentration during product selection; infuse as slowly as indication and stability allow (consult "Immune Globulin Product Comparison" for additional details). Dosage expressed as mg/kg or mL/kg dependent upon route of administration; use extra caution to ensure accuracy.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ecf3e4f2-5f83-4425-8fbc-aea9ef68ffb7">Acute disseminated encephalomyelitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute disseminated encephalomyelitis (ADEM):</b> Limited data available: Children and Adolescents: IV: 1,000 mg/kg/dose once daily for 2 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17397768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17397768'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ba12c275-3856-4082-b3fe-9ca5056e84bc">Colitis due to <i>Clostridioides difficile</i>, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Colitis due to <i>Clostridioides</i>
<i>difficile</i>, chronic:</b> Limited data available: Infants and Children: IV: 400 mg/kg/dose every 3 weeks resulted in resolution of colitis symptoms during treatment; duration of therapy was unclear (n=5; age range: 6 to 37 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20924675','lexi-content-ref-1901084','lexi-content-ref-10997362']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20924675','lexi-content-ref-1901084','lexi-content-ref-10997362'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="11273d54-f7ad-4b30-9669-1c98bba84d14">Dermatomyositis, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dermatomyositis, refractory:</b> Limited data available: Children: IV: 1,000 mg/kg/dose once daily for 2 days; <b>Note:</b> If maintenance therapy is required, the dose and frequency should be based on clinical response and doses should not exceed 2,000 mg/kg per treatment course (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17397768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17397768'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="db9f46bf-88c1-4c41-a77e-f41b37fdaf7b">Guillain-Barré syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Guillain-Barré syndrome:</b> Limited data available: Various regimens have been used:</p>
<p style="text-indent:-2em;margin-left:4em;">Children: IV: 1,000 mg/kg/dose once daily for 2 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17397768','lexi-content-ref-15995024']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17397768','lexi-content-ref-15995024'])">Ref</a></span>) <b>or</b> 400 mg/kg/dose once daily for 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21745374','lexi-content-ref-15995024']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21745374','lexi-content-ref-15995024'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9a9037c6-9567-4f04-a071-768cc90be35d">Hematopoietic cell transplantation with hypogammaglobulinemia, prevention of bacterial infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic cell transplantation (HCT) with hypogammaglobulinemia (IgG &lt;400 mg/dL), prevention of bacterial infection:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>): <b>Note:</b> Increase dose or frequency to maintain IgG concentration &gt;400 mg/dL.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Within first 100 days after HCT: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children (Allogeneic HCT recipients): IV: 400 mg/kg/dose once <b>monthly</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: IV: 500 mg/kg/dose once weekly.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>&gt;100 days after HCT:</i> Infants, Children, and Adolescents: IV: 500 mg/kg/dose every 3 to 4 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="89f0f4e7-dae6-49d6-bd76-ae07d0658b03">Hepatitis A, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatitis A, prophylaxis:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Preexposure prophylaxis upon travel into endemic areas (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32614811']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32614811'])">Ref</a></span>):</i>
<b>Note:</b> Hepatitis A vaccine preferred for pediatric patients ≥6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32614811']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32614811'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: GamaSTAN:</p>
<p style="text-indent:-2em;margin-left:8em;">Anticipated duration of risk ≤1 month: IM: 0.1 <b>mL</b>/kg/dose as a single dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Anticipated duration of risk 1 to 2 months: IM: 0.2 <b>mL</b>/kg/dose as a single dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Anticipated duration of risk ≥2 months: IM: 0.2 <b>mL</b>/kg/dose every 2 months.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postexposure prophylaxis</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32614811']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32614811'])">Ref</a></span>): <b>Note: </b>Hepatitis A vaccine preferred for pediatric patients ≥12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32614811']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32614811'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: GamaSTAN: IM: 0.1 <b>mL</b>/kg/dose as a single dose given within 14 days of exposure and prior to manifestation of disease.</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: GamaSTAN: IM: 0.1 <b>mL</b>/kg/dose as a single dose given within 14 days of exposure and prior to manifestation of disease; not needed if at least 1 dose of hepatitis A vaccine was given previously or as part of postexposure prophylaxis unless patient has chronic liver disease or is immunocompromised.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="061dab84-b6fa-4099-a8e9-5f6605b6e7a9">Bacterial infection prophylaxis in patients with HIV and hypogammaglobulinemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bacterial infection prophylaxis in patients with HIV and hypogammaglobulinemia: </b>Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2016'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Primary prophylaxis for serious bacterial infection in patients with hypogammaglobulinemia (IgG &lt;400 mg/dL):</i> IV: 400 mg/kg/dose every 2 to 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Secondary prophylaxis for invasive bacterial infections:</i> Should only be used if subsequent infections are frequent severe infections (&gt;2 infections during a 1-year period): IV: 400 mg/kg/dose every 2 to 4 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58acdf8a-6a05-45e7-a020-bd4c6e72f2ed">Immune thrombocytopenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Immune thrombocytopenia (ITP): </b></p>
<p style="text-indent:-2em;margin-left:4em;">Carimune NF 6%: Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Acute therapy: IV: 400 mg/kg/dose once daily for 2 to 5 days to maintain platelet count ≥30,000/mm<sup>3</sup> and/or to control significant bleeding. If platelet response is adequate (30,000 to 50,000/mm<sup>3</sup>) after the first 2 doses, then may discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">Chronic therapy: IV: 400 mg/kg/dose as a single infusion to maintain platelet count ≥30,000/mm<sup>3</sup> and/or to control significant bleeding; may increase to 800 to 1,000 mg/kg/dose if response inadequate.</p>
<p style="text-indent:-2em;margin-left:4em;">Flebogamma DIF 10%: Children ≥2 years and Adolescents: Chronic therapy: IV: 1,000 mg/kg/dose once daily for 2 consecutive days.</p>
<p style="text-indent:-4em;margin-left:6em;">Gammaked, Gamunex-C: Infants, Children, and Adolescents: Acute or chronic therapy: IV: 400 mg/kg/dose once daily for 5 consecutive days or 1,000 mg/kg/dose once daily for 2 consecutive days; if an adequate platelet response is observed after the initial 1,000 mg/kg/dose, then the subsequent dose may be held.</p>
<p style="text-indent:-2em;margin-left:4em;">Privigen: Adolescents ≥15 years: Chronic therapy: IV: 1,000 mg/kg/dose once daily for 2 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3323746a-ced0-47b1-98d4-d1c674bf951f">Kawasaki disease, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Kawasaki disease, treatment: </b>Limited data available: <b>Note: </b>Use in combination with aspirin; may consider the addition of corticosteroids in patients at high risk for IVIG resistance or developing coronary artery aneurysms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35257507','lexi-content-ref-28356445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35257507','lexi-content-ref-28356445'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: IV: 2,000 mg/kg as a single dose infused over 8 to 12 hours; usually administered within 10 days of disease onset; however, may be administered &gt;10 days from onset in patients with delayed diagnosis or with persistent symptoms of systemic inflammation with persistent fever and/or coronary artery aneurysms. If signs and symptoms persist ≥36 hours after completion of the infusion, retreatment with a second dose of 1,000 or 2,000 mg/kg infusion may be considered with or without corticosteroids; a lower second dose has been suggested to minimize risk for adverse drug reactions (eg, hemolytic anemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33532696','lexi-content-ref-35257507','lexi-content-ref-28356445','lexi-content-ref-29951056','lexi-content-ref-23485027','lexi-content-ref-1709446','lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33532696','lexi-content-ref-35257507','lexi-content-ref-28356445','lexi-content-ref-29951056','lexi-content-ref-23485027','lexi-content-ref-1709446','lexi-content-ref-AAP.2'])">Ref</a></span>). <b>Note: </b>A maximum dose has not been defined; a reasonable maximum dose of 100 to 140 g/dose has been suggested during times of drug shortages or when cost is a consideration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35257507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35257507'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="01dcbd5b-32d8-484e-8773-8dcf77f39e13">Measles, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Measles, prophylaxis:</b>
<b>Note:</b> Route of administration varies with product; verify route prior to administration.</p>
<p style="text-indent:-2em;margin-left:4em;">ACIP recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23760231']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23760231'])">Ref</a></span>): Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Preexposure prophylaxis (eg, during an outbreak, travel to endemic area):</i>
<b>Note:</b> Indicated for patients already receiving immune globulin therapy.</p>
<p style="text-indent:-2em;margin-left:8em;">IV: ≥400 mg/kg/dose within 3 weeks before anticipated exposure.</p>
<p style="text-indent:-2em;margin-left:8em;">SUBQ: 200 mg/kg/dose once weekly for 2 consecutive weeks prior to anticipated exposure. <b>Note:</b> Not all immune globulin preparations may be administered by the SUBQ route; consult product labeling for additional information as market availability may change.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Postexposure prophylaxis (in any person without evidence of measles immunity):</i></p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:10em;">IM: 0.5 <b>mL</b>/kg/dose (maximum dose: 15 <b>mL</b>/dose) within 6 days of exposure; in adults, doses &gt;10 mL should be split into multiple injections and administered at different sites; in pediatric patients, may also split doses &lt;10 mL based on patient size. Note: Not all immune globulin preparations may be administered by the IM route; of the products currently available on the market, GamaSTAN may be given IM; consult product labeling for additional information as market availability may change. GamaSTAN manufacturer labeling suggests a lower IM dose; however, this dosing was based on previous immune globulin donor potency concentrations; recent data indicates that potency from current donor populations has decreased (ie, measles immunity now from vaccinations instead of immunity from disease) requiring a higher IM immune globulin dose (0.5 <b>mL</b>/kg) in all patients without evidence of measles immunity to ensure adequate serum titers.</p>
<p style="text-indent:-2em;margin-left:10em;">IV: 400 mg/kg/dose within 6 days of exposure.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Product-specific dosing:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Cutaquig: <b>SUBQ infusion:</b> Patients with primary humoral immunodeficiency: Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Preexposure prophylaxis: SUBQ: Increase dose to ≥245 mg/kg/dose once weekly or equivalent if dosing is not on a weekly schedule (if current dose is less).</p>
<p style="text-indent:-2em;margin-left:6em;">Cuvitru: <b>SUBQ infusion:</b> Patients with primary humoral immunodeficiency: Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Preexposure prophylaxis: SUBQ: Increase dose to ≥230 mg/kg/dose once weekly or equivalent if dosing is not on a weekly schedule (if current dose is less).</p>
<p style="text-indent:-2em;margin-left:6em;">Flebogamma DIF 5%, Gammagard Liquid, Gammagard S/D, Gammaplex 5% and 10%: <b>IV: </b>Patients with primary humoral immunodeficiency: Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Preexposure prophylaxis: IV: Increase dose to ≥530 mg/kg every 3 to 4 weeks (if current dose is less).</p>
<p style="text-indent:-2em;margin-left:8em;">Postexposure prophylaxis: IV: 400 mg/kg once as soon as possible and within 6 days of exposure.</p>
<p style="text-indent:-2em;margin-left:6em;">GamaSTAN: <b>IM:</b> Infants, Children, and Adolescents</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Immunocompromised:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Postexposure prophylaxis: IM: 0.5 <b>mL</b>/kg immediately; maximum dose: 15 <b>mL</b>/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Immunocompetent: </i></p>
<p style="text-indent:-2em;margin-left:10em;">Postexposure prophylaxis: IM: 0.25 <b>mL</b>/kg within 6 days of exposure. <b>Note:</b> CDC/ACIP recommend 0.5 <b>mL</b>/kg/dose for all patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23760231']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23760231'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Gammaked, Gamunex-C: <b>IV:</b> Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Preexposure prophylaxis: IV: Increase dose to ≥400 mg/kg every 3 to 4 weeks just prior to expected exposure (if current dose is less).</p>
<p style="text-indent:-2em;margin-left:8em;">Postexposure prophylaxis: IV: 400 mg/kg once as soon as possible after exposure.</p>
<p style="text-indent:-2em;margin-left:6em;">Hizentra: <b>SUBQ infusion: </b>Patients with primary humoral immunodeficiency: Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Preexposure prophylaxis: SUBQ:</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Patients receiving weekly or more frequent dosing receiving &lt;200 mg/kg weekly:</i> Increase dose to ≥200 mg/kg/dose weekly for 2 consecutive weeks.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Patients receiving biweekly dosing:</i> Increase dose to ≥400 mg/kg once (if current dose is less).</p>
<p style="text-indent:-2em;margin-left:8em;">Postexposure prophylaxis (regardless of prior dosing schedule): SUBQ: 400 mg/kg administered as soon as possible after exposure.</p>
<p style="text-indent:-2em;margin-left:6em;">Octagam 5%: <b>IV:</b> Patients with primary humoral immunodeficiency: Children ≥6 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Preexposure prophylaxis: IV: Increase dose to ≥530 mg/kg every 3 to 4 weeks (if current dose is less).</p>
<p style="text-indent:-2em;margin-left:8em;">Postexposure prophylaxis: IV: 400 mg/kg once as soon as possible and within 6 days of exposure.</p>
<p style="text-indent:-2em;margin-left:6em;">Privigen: <b>IV:</b> Patients with primary humoral immunodeficiency: Children ≥3 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Preexposure prophylaxis: IV: Increase dose to ≥530 mg/kg every 3 to 4 weeks (if current dose is less).</p>
<p style="text-indent:-2em;margin-left:8em;">Postexposure prophylaxis: IV: 400 mg/kg once as soon as possible and within 6 days of exposure.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="af40f154-7312-412d-a28e-8e77cdc833ae">Multiple sclerosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple sclerosis (relapsing-remitting, when other therapies cannot be used):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Dosage regimen variable; optimal dose not established: IV: 1,000 mg/kg/dose once <b>monthly</b>, with or without an induction of 400 mg/kg/day for 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17397768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17397768'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2409ba83-3fab-48ac-bd75-41b00b70b569">Multisystem inflammatory syndrome in children associated with SARS-CoV-2</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Recommended for initial therapy in combination with glucocorticoids (ie, methylprednisolone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35118829','lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35118829','lexi-content-ref-NIH.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 2,000 mg/kg once, infused over ~12 hours; maximum dose: 100 <b>g </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35118829','lexi-content-ref-33557873','lexi-content-ref-NIH.1','lexi-content-ref-33876782']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35118829','lexi-content-ref-33557873','lexi-content-ref-NIH.1','lexi-content-ref-33876782'])">Ref</a></span>). <b>Note:</b> If cardiac function is impaired or patient is fluid overloaded, consider slowing administration rate (eg, ≥16 hours) or splitting into 2 infusions (1,000 mg/kg/dose daily for 2 days); monitor fluid status closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35118829','lexi-content-ref-33557873','lexi-content-ref-NIH.1','lexi-content-ref-33876782']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35118829','lexi-content-ref-33557873','lexi-content-ref-NIH.1','lexi-content-ref-33876782'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3b2563df-329d-4d91-8f27-2a2bfaa15782">Myasthenia gravis, severe exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myasthenia gravis, severe exacerbation:</b> Limited data available: Children: IV: 400 to 1,000 mg/kg/dose once daily over 2 to 5 days for a total dose of 2,000 mg/kg; if additional therapy required, dose should be based on clinical response and titrated to minimum effective dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17397768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17397768'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7424aa58-c6b5-4af4-90aa-22eccdf87e98">Myocarditis, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myocarditis, acute:</b> Limited data available: Infants, Children, and Adolescents: IV: 2,000 mg/kg as a single dose. A cohort study of 21 children showed improvement in LVF recovery and survival at 1 year as compared to untreated historical cohort (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8281654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8281654'])">Ref</a></span>); efficacy results are variable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15680069','lexi-content-ref-15155409','lexi-content-ref-19936586']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15680069','lexi-content-ref-15155409','lexi-content-ref-19936586'])">Ref</a></span>); the largest data analysis did not show clear clinical benefit nor positive impact on survival (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19936586']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19936586'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="add75990-a0aa-4800-abb6-33f5bc925d68">Primary immunodeficiency disorders</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary immunodeficiency disorders:</b> Adjust dose/frequency based on desired IgG concentration and clinical response; a trough IgG concentration of ≥500 mg/dL has been recommended by some experts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15945566']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15945566'])">Ref</a></span>); consult product specific labeling for appropriate age groups.</p>
<p style="text-indent:-2em;margin-left:4em;">IV infusion:</p>
<p style="text-indent:-2em;margin-left:6em;">Asceniv: Children ≥12 years and Adolescents: IV: 300 to 800 mg/kg every 3 to 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Bivigam: Children ≥6 years and Adolescents: IV: 300 to 800 mg/kg every 3 to 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Carimune NF: Infants, Children, and Adolescents: IV: 400 to 800 mg/kg/dose every 3 to 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Flebogamma 5% DIF, Gammagard Liquid, Gammagard S/D, Gammaked, Gamunex-C, Panzyga: Children ≥2 years and Adolescents: IV: 300 to 600 mg/kg/dose every 3 to 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Gammaplex 5% and 10%: Children ≥2 years and Adolescents: IV: 300 to 800 mg/kg every 3 to 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Octagam 5%: Children ≥6 years and Adolescents: IV: 300 to 600 mg/kg/dose every 3 to 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Privigen: Children ≥3 years and Adolescents: IV: 200 to 800 mg/kg/dose every 3 to 4 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">SUBQ infusion:</p>
<p style="text-indent:-2em;margin-left:6em;">Cutaquig, Cuvitru: Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients switching from IGIV therapy</i>: <b>SUBQ infusion:</b> Begin 1 week after last immune globulin IV dose. Use the following equations to calculate initial dose:</p>
<p style="text-indent:-2em;margin-left:10em;">Initial weekly dosing: Dose (grams) = (IV dose [grams] divided by IV dose interval [weeks]), then multiply this dose by 1.3 (dose adjustment factor). <b>Note:</b> To convert the dose (in grams) to mL, multiply the calculated dose (in grams) by 5 (for Cuvitru) or by 6 (for Cutaquig).</p>
<p style="text-indent:-2em;margin-left:10em;">Biweekly dosing (grams): Multiply the calculated weekly dose by 2.</p>
<p style="text-indent:-2em;margin-left:10em;">Frequent dosing (2 to 7 times per week) (grams): Divide the calculated weekly dose by the desired number of times per week.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients switching from another IG SubQ product:</i>
<b>SUBQ infusion:</b></p>
<p style="text-indent:-2em;margin-left:10em;">Weekly dosing (grams): Weekly dose is the same as the prior immune globulin subcutaneous weekly dose.</p>
<p style="text-indent:-2em;margin-left:10em;">Biweekly dosing (grams): Multiply the calculated weekly dose by 2.</p>
<p style="text-indent:-2em;margin-left:10em;">Frequent dosing (2 to 7 times per week) (grams): Divide the calculated weekly dose by the desired number of administration times per week.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">Gammagard Liquid, Gammaked, Gamunex-C: Children ≥2 years and Adolescents: <b>SUBQ infusion:</b> Begin 1 week after last IV dose. Use the following equation to calculate initial dose:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial weekly dose: Dose (grams) = (1.37 x IV dose [grams]) divided by (IV dose interval [weeks]); <b>Note:</b> For subsequent doses, refer to product labeling. <b>Note:</b> To convert the dose (in grams) to mL, multiply the calculated dose (in grams) by 10.</p>
<p style="text-indent:-2em;margin-left:6em;">Hizentra: Children ≥2 years and Adolescents: <b>SUBQ infusion:</b> For weekly dosing or frequent (up to daily), begin 1 week after last IV or SUBQ infusion. For biweekly dosing, begin 1 or 2 weeks after last IV infusion or 1 week after the last SUBQ weekly infusion. <b>Note:</b> Patient should have received an IV immune globulin routinely for at least 3 months before switching to SUBQ. Use the following equation to calculate initial dose:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial <b>weekly</b> dose: Dose (grams) = (Previous IV dose [grams]) divided by (IV dose interval [weeks]) then multiply by 1.37; if switching from a different SUBQ formulation to Hizentra, maintain previous weekly SUBQ dose initially. <b>Note:</b> To convert the dose (in grams) to mL, multiply the calculated dose (in grams) by 5.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Provided the total weekly dose is maintained, any dosing interval from daily up to biweekly (every 2 weeks) may be used. Use the following calculations to calculate frequent or biweekly dosing:</p>
<p style="text-indent:-2em;margin-left:10em;">Biweekly dose (grams): Dose = Calculated or previous weekly SUBQ dose (grams) multiplied by 2.</p>
<p style="text-indent:-2em;margin-left:10em;">Frequent (2 to 7 times per week) dosing: Dose (grams) = Calculated or previous weekly dose (grams) divided by the desired number of times per week (eg, for 3 times per week dosing, divide weekly dose by 3).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> For subsequent doses refer to product labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">Xembify: Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients switching from another IG SUBQ product:</i>
<b>SUBQ infusion:</b> Weekly dose is the same as the prior immune globulin subcutaneous weekly dose (grams).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients switching from IGIV therapy:</i>
<b>SUBQ infusion:</b> Begin treatment 1 week after patient's last immune globulin IV.</p>
<p style="text-indent:-2em;margin-left:10em;">Initial weekly dosing (grams): Previous IV dose (grams) divided by IV dose interval (weeks) then multiply by 1.37. <b>Note:</b> To convert the dose (in grams) to mL, multiply the calculated dose (in grams) by 5.</p>
<p style="text-indent:-2em;margin-left:12em;">
<b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>
<p style="text-indent:-2em;margin-left:10em;">Frequent (2 to 7 times per week) dosing (grams): Divide the calculated weekly dose by the desired number of times per week.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6d1f4034-d2e3-47bf-ac30-88d84cbbe661">Rubella, prophylaxis during pregnancy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rubella, prophylaxis during pregnancy (postexposure):</b> GamaSTAN: Adolescents: IM: 0.55 <b>mL</b>/kg/dose as a single dose within 72 hours of exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9639369']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9639369'])">Ref</a></span>); <b>Note:</b> Not recommended for routine use; may reduce, but not eliminate, risk for rubella. In adults, total dose volumes &gt;10 mL should be split into multiple injections given at different sites.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7189c7a2-6c68-44b7-88e9-9e725ae13d68">Stevens-Johnson syndrome/toxic epidermal necrolysis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: Usual dose: 1,500 to 2,000 mg/kg total dose as a single dose or divided over 2 to 4 days; dosing based on retrospective reviews and case reports; efficacy results are variable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19811851','lexi-content-ref-11036849','lexi-content-ref-12271299']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19811851','lexi-content-ref-11036849','lexi-content-ref-12271299'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b1b1fc11-b0af-4a6e-9e2e-022bee28582b">Varicella-zoster, postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella-zoster, postexposure prophylaxis (independent of HIV-status):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: <b>Note:</b> Use only if varicella-zoster immune globulin is unavailable.</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 400 mg/kg as a single infusion as soon as possible and within 10 days of exposure; ideally within 96 hours of exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2016','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2016','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IM: GamaSTAN: 0.6 to 1.2 <b>mL</b>/kg/dose as a single dose within 72 hours of exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-217893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-217893'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51113738"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:4em;">IV: Use with caution due to risk of immune globulin-induced renal dysfunction; the rate of infusion and concentration of solution should be minimized. Discontinue if renal function deteriorates during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">SubQ infusion: There are no dosage adjustments provided in the manufacturer's labeling; consider lower, more frequent dosing.</p></div>
<div class="block dohp drugH1Div" id="F51113739"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">IM, IV, SubQ infusion: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F11513277"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="16471" href="/d/html/16471.html" rel="external">see "Immune globulin (Intravenous, subcutaneous, and intramuscular): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Always administer each initial IV dose under medical supervision. Ensure adequate hydration when using formulations containing certain stabilizers (eg, sucrose) and for patients with risk factors for thrombosis and/or renal complications (eg, preexisting renal insufficiency, diabetes, &gt;65 years of age, heart disease, paraproteinemia, concomitant nephrotoxic agents) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24051350','lexi-content-ref-17699296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24051350','lexi-content-ref-17699296'])">Ref</a></span>). Many patients do not require premedication prior to receiving IVIG; however, some clinicians may consider administering premedication (eg, acetaminophen, a nonsteroidal anti-inflammatory drug, a glucocorticoid, and/or diphenhydramine), especially if there have been prior reactions or other reasons for special concern (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ballow.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ballow.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Dosage is expressed as mg/kg or mL/kg and is dependent upon route of administration; use extra caution to ensure accuracy. Product-specific dosing is provided where applicable.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information: </b>Not all products are interchangeable with regard to route of administration; consult manufacturer labeling. Several intravenous immune globulin (IVIG) 10% formulations FDA-approved for IV administration only may be administered as a SUBQ infusion based on clinical judgment and patient tolerability. In contrast, do<b> not </b>give higher concentration SUBQ products (eg, 20% [Cuvitru, Hizentra, Xembify]) or IM products (eg, 16% [GamaSTAN {Canadian product}]) intravenously.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7073a9e6-1a73-4b88-8882-0c814488709d">Antibody-mediated rejection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antibody-mediated rejection, treatment (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Optimal dose, frequency, and duration are unknown and vary based on institutional protocols. Dose may require large volume of fluid. These are only example regimens; dosing is center dependent.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Heart transplantation</i>:</b>
<b>IV:</b> 1 to 2 g/kg in 2 to 4 divided doses over 1 to 3 days as part of an appropriate combination regimen; if plasmapheresis is utilized, administer 100 mg/kg after each session. Regimen may be re-dosed monthly, if necessary, based on response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25838326','lexi-content-ref-Eisen.1','lexi-content-ref-20643330','lexi-content-ref-15196059']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25838326','lexi-content-ref-Eisen.1','lexi-content-ref-20643330','lexi-content-ref-15196059'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Intestine transplantation: </i>IV:</b> 10 g once daily on nonplasmapheresis days, as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24279605']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24279605'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Kidney transplantation: </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Antibody-mediated rejection ≤1 year after transplant:</i>
<b>IV:</b> 100 mg/kg after each plasmapheresis session then 500 mg to 1 <b>g</b>/kg per day for 1 to 2 days after final session (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Parajuli.1','lexi-content-ref-26555944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Parajuli.1','lexi-content-ref-26555944'])">Ref</a></span>); some experts recommend a total cumulative target dose of ≥1 <b>g</b>/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Parajuli.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Parajuli.1'])">Ref</a></span>). Use as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Parajuli.1','lexi-content-ref-26555944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Parajuli.1','lexi-content-ref-26555944'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Antibody-mediated rejection &gt;1 year after transplant:</i>
<b>IV:</b> 200 mg/kg every 2 weeks for 3 doses as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Parajuli.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Parajuli.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Liver transplantation</i>: IV: </b>100 <b>mg</b>/kg after each plasmapheresis session; up to a total of 1 to 2 <b>g</b>/kg at the end of the last plasmapheresis session. Use as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34480762']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34480762'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Lung transplantation</i>:</b>
<b>IV:</b> 500 mg/kg to 2 <b>g</b>/kg as part of an appropriate combination regimen (doses &gt;1 g/kg are typically divided into 2 doses and given over 2 days). This regimen may be re-dosed monthly, if necessary, based on response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20558084','lexi-content-ref-23953920']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20558084','lexi-content-ref-23953920'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Pancreas transplantation</i>: IV: </b>2 <b>g</b>/kg total (administered in divided doses), as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32492226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32492226'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fba58591-c5ea-4b03-b220-0ec7a9a57d18">Antiviral prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antiviral prophylaxis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Hepatitis A, prophylaxis (adjunctive agent):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Hepatitis A vaccine alone is preferred for most individuals; IVIG may be administered in combination with hepatitis A vaccine (at a different anatomical site) in high-risk settings, or alone in individuals who are allergic to hepatitis A vaccine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32614811']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32614811'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Preexposure prophylaxis upon travel into endemic areas (alternative agent) (GamaSTAN, GamaSTAN S/D [Canadian product]):</i></p>
<p style="text-indent:-2em;margin-left:8em;">Anticipated risk of exposure &lt;1 month: <b>IM:</b> 0.1 <b>mL</b>/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32614811']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32614811'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Anticipated risk of exposure 1 to 2 months: <b>IM:</b> 0.2 <b>mL</b>/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32614811']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32614811'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Anticipated risk of exposure ≥2 months: <b>IM:</b> 0.2 <b>mL</b>/kg every 2 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32614811']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32614811'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Postexposure prophylaxis (alternative agent)</i>
<i>(GamaSTAN, GamaSTAN S/D [Canadian product]):</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IM:</b> 0.1 <b>mL</b>/kg given as soon as possible within 14 days of exposure and/or prior to manifestation of disease; not needed if at least 1 dose of hepatitis A vaccine was given at ≥1 month before exposure, unless patient has HIV infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32614811','lexi-content-ref-30973852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32614811','lexi-content-ref-30973852'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Measles, prophylaxis:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Measles, preexposure prophylaxis in patients with primary humoral immunodeficiency at risk of measles exposure (eg, during an outbreak, travel to endemic area) who are currently receiving immune globulin therapy:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:10em;">Patients receiving Gammagard Liquid, Gammagard S/D, Gammaked, Gammaplex 5%, Gammaplex 10%, Gamunex-C, Flebogamma DIF 5%, Flebogamma DIF 10%, Octagam 5%, or Privigen:</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>If prior routine dose is &lt;400 mg/kg (Gammaked only) <b>or</b> &lt;530 mg/kg (other products):</i> Give at least 400 mg/kg (Gammaked only) <b>or</b> at least 530 mg/kg (other products) as soon as possible before expected exposure followed by resumption of prior dosing in 3 to 4 weeks.</p>
<p style="text-indent:-2em;margin-left:10em;">Patients receiving Panzyga:</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>If prior dose &lt;530 mg/kg</i>: Increase dose to at least 530 mg/kg immediately before expected exposure; increased dose provides adequate serum level for at least 22 days.</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>If prior dose ≥530 mg/kg</i>: Maintain current dose.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:10em;">Patients receiving Cutaquig:</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>If prior weekly dose &lt;245 mg/kg</i>: Increase dose to 245 mg/kg weekly.</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>If prior weekly dose ≥245 mg/kg</i>: Maintain current dose.</p>
<p style="text-indent:-2em;margin-left:10em;">Patients receiving Cuvitru:</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>If prior weekly (or weekly equivalent) dose &lt;230 mg/kg</i>: Increase dose to at least 230 mg/kg weekly or the weekly equivalent of 230 mg/kg for dosing intervals other than weekly.</p>
<p style="text-indent:-2em;margin-left:10em;">Patients receiving Hizentra:</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>If prior dosing is weekly or more frequent:</i> Ensure total weekly dose of ≥200 mg/kg for 2 consecutive weeks followed by resumption of prior dosing schedule.</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>If prior dosing is biweekly:</i> Administer at least 400 mg/kg once followed by resumption of prior dosing schedule.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Measles, postexposure prophylaxis in patients with primary humoral immunodeficiency currently receiving SUBQ or IV immune globulin therapy; patients who are immunocompromised without evidence of immunity; and pregnant or severely immunocompromised patients without evidence of measles immunity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23760231']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23760231'])">Ref</a></span>):</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV: </b>400 mg/kg as a single dose as soon as possible and within 6 days of exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23760231']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23760231'])">Ref</a></span>). For patients with primary humoral immunodeficiency currently receiving SUBQ or IV immune globulin therapy, resume prior dosing schedule.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>SUBQ (Hizentra only): </b>400 mg/kg as a SUBQ infusion as soon as possible and within 6 days of exposure followed by resumption of prior dosing schedule (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23760231','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23760231','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> This regimen is generally used for patients with primary humoral immunodeficiency currently receiving Hizentra.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Varicella, postexposure prophylaxis (alternative agent): </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Varicella zoster immune globulin is preferred; IVIG may be used if varicella zoster immune globulin is unavailable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17585291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17585291'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 400 mg/kg administered as a single dose within 10 days but, ideally, within 96 hours of exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31890472']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31890472'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM (</b>
<b>GamaSTAN, GamaSTAN S/D [Canadian product])</b>
<b>:</b> 0.6 to 1.2 <b>mL</b>/kg once within 72 hours of exposure. <b>Note:</b> For patients at risk of thrombosis, administer at the lower end of the recommended dosage range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-217893','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-217893','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e08be426-44bf-414e-8751-bbf07bf0369a">Chronic inflammatory demyelinating polyneuropathy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic inflammatory demyelinating polyneuropathy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial:</i> 2 g/kg administered in divided doses over 2 to 5 consecutive days (eg, 400 mg/kg once daily for 5 days) followed by maintenance dosing (maximum total daily dose: 1 g/kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18796075','lexi-content-ref-8813271','lexi-content-ref-18178525','lexi-content-ref-11222785']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18796075','lexi-content-ref-8813271','lexi-content-ref-18178525','lexi-content-ref-11222785'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance:</i> 1 g/kg administered as a single infusion over 1 day or divided into 2 doses over 2 consecutive days, every 3 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18178525']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18178525'])">Ref</a></span>). Continue maintenance therapy for 2 to 3 months before determining response to therapy. Further tapering of dose or frequency and the duration of maintenance therapy are individualized depending upon clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lewis.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lewis.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ (alternative route):</b>
<b>Note:</b> May be used as maintenance therapy for patients who respond to initial IVIG therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lewis.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lewis.1'])">Ref</a></span>). Begin maintenance therapy 1 week after last IVIG infusion.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance</i>: 200 to 400 mg/kg/<b>week</b> administered in 1 or 2 sessions over 1 or 2 consecutive days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29122523']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29122523'])">Ref</a></span>). For worsening symptoms, consider restarting IVIG using dosing above.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="abae66fe-387f-4e84-acb1-28fe0951cafe">Dermatomyositis/Polymyositis, severe, life-threatening or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dermatomyositis/Polymyositis</b>
<b>, severe, life-threatening or refractory:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For dermatomyositis, use in combination with other agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18796075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18796075'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 g/kg per day on 2 consecutive days every 4 weeks <b>or</b> 2 g/kg as a single dose every 4 weeks (total monthly dose: 2 g/kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36198179','lexi-content-ref-11840450','lexi-content-ref-8247075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36198179','lexi-content-ref-11840450','lexi-content-ref-8247075'])">Ref</a></span>). For patients who develop intolerable adverse effects, some experts give 1 g/kg per day once every 2 weeks. Dosing interval may be lengthened once complete clinical response is achieved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vleugels.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vleugels.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ (alternative route):</b> 500 mg/kg once weekly (total monthly dose: 2 g/kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20858553','lexi-content-ref-Targoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20858553','lexi-content-ref-Targoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration:</i> Full clinical effect may take up to 6 months. Relapse may occur upon treatment discontinuation; continued treatment may be necessary to maintain control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vleugels.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vleugels.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bdbd75f7-2d50-44ba-a180-f2f0a54bb04c">Encephalitis, immune checkpoint inhibitor-induced, severe or progressive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Encephalitis, immune checkpoint inhibitor-induced, severe or progressive (off-label use): Note: </b>Initiate treatment early in the course of illness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28495807']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28495807'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>400 mg/kg once daily for 5 days (in combination with IV methylprednisolone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="73aab08c-efe3-4da0-a74b-d9b4d358e86a">Encephalomyelitis, acute disseminated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Encephalomyelitis, acute disseminated (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients in whom first-line therapy with high-dose glucocorticoids has failed while evaluating for alternative diagnoses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17397768','lexi-content-ref-Waldman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17397768','lexi-content-ref-Waldman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>400 mg/kg once daily for 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17397768','lexi-content-ref-11954856','lexi-content-ref-Waldman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17397768','lexi-content-ref-11954856','lexi-content-ref-Waldman.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="db9f46bf-88c1-4c41-a77e-f41b37fdaf7b">Guillain-Barré syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Guillain-Barré syndrome (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For nonimmunotherapy-induced Guillain-Barré syndrome, initiate IVIG within 4 weeks of symptom onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Muley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Muley.1'])">Ref</a></span>). For immune checkpoint inhibitor-induced Guillain-Barré syndrome, initiate treatment early in the course of illness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28495807']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28495807'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 400 mg/kg once daily for 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18796075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18796075'])">Ref</a></span>). Re-treatment is not recommended due to increased risk of adverse effects without additional benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Muley.1','lexi-content-ref-33743237']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Muley.1','lexi-content-ref-33743237'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Guillain-Barré </i></b>
<b>
<i>syndrome, immune checkpoint inhibitor-induced, grade 3 or 4 (severe): </i>IV: </b>400 mg/kg once daily for 5 days in combination with corticosteroid therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392','lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392','lexi-content-ref-34172516'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2480cc9-7f51-4cea-8770-9bc48e5e55ea">Hypogammaglobulinemia, prophylaxis against bacterial infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypogammaglobulinemia, prophylaxis against bacterial infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Acquired secondary to malignancy: </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Reserve for patients who have had recurrent infections and have a low serum IgG (eg, &lt;300 to 500 mg/dL); routine prophylaxis not recommended and thresholds for treatment vary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21908504','lexi-content-ref-29540348','lexi-content-ref-Morrison.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21908504','lexi-content-ref-29540348','lexi-content-ref-Morrison.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Initial: 200 to 400 mg/kg given as a single dose once every 3 to 4 weeks. Adjust dose or frequency to maintain IgG concentration &gt;500 to 700 mg/dL and/or based on response to therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17397769','lexi-content-ref-7909099','lexi-content-ref-2901668','lexi-content-ref-Morrison.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17397769','lexi-content-ref-7909099','lexi-content-ref-2901668','lexi-content-ref-Morrison.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Hematopoietic cell transplantation (off-label use):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Reserve for patients who have had recurrent infections and have a low serum IgG (eg, &lt;300 to 500 mg/dL); routine prophylaxis not recommended and thresholds for treatment vary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wingard.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wingard.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>≤100 days post–hematopoietic cell transplantation:</i>
<b>IV:</b> 500 mg/kg administered as a single dose once weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>&gt;100 days post–hematopoietic cell transplantation:</i>
<b>IV: </b>500 mg/kg administered as a single dose every 3 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Adjust dose or frequency to maintain IgG concentration &gt;500 to 700 mg/dL and/or based on patient's response to therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wingard.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wingard.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Primary humoral immunodeficiency disorders</i>:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 400 to 600 mg/kg as a single dose once every 3 to 4 weeks; adjust dose based on clinical condition and response (see <b>"Note" </b>below). Dosage range: 200 to 800 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Orange.1','lexi-content-ref-28041678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Orange.1','lexi-content-ref-28041678'])">Ref</a></span>). Consider using lower concentrations (eg, Carimune NF 3%) in previously untreated patients; may use higher concentrations if tolerated.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>SUBQ:</b> 100 to 200 mg/kg once weekly; adjust dose based on clinical condition and response (see <b>"Note" </b>below). Dosage range: 200 to 800 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Orange.1','lexi-content-ref-28041678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Orange.1','lexi-content-ref-28041678'])">Ref</a></span>). May facilitate absorption by administering along with hyaluronidase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28871852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28871852'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">HyQvia: See manufacturer's labeling for initial ramp-up schedule (initiating treatment with a full monthly dose has not been evaluated).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Consistent IgG trough concentrations are typically achieved after 3 to 6 months of regular therapy. Adjust dose to maintain goal IgG trough 500 to 800 mg/dL; occasionally, a goal of &gt;1 g/dL is required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26371839','lexi-content-ref-Orange.1','lexi-content-ref-28041678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26371839','lexi-content-ref-Orange.1','lexi-content-ref-28041678'])">Ref</a></span>). Refer to <b>"Switching from IV to SUBQ infusion dosing or</b>
<b> switching between SUBQ products" </b>below for dosing and administration recommendations when switching between products.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58acdf8a-6a05-45e7-a020-bd4c6e72f2ed">Immune thrombocytopenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Immune thrombocytopenia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Immune thrombocytopenia (adjunctive or alternative agent):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>For patients who require a rapid increase in platelet count, those who do not respond to glucocorticoids, and those who cannot tolerate glucocorticoids. IVIG may also be used for patients with critical bleeding or a need for urgent surgery or procedures (eg, pregnancy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Arnold.1','lexi-content-ref-21325604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Arnold.1','lexi-content-ref-21325604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 1 g/kg once daily for 1 or 2 days; second dose may be withheld if adequate platelet response (eg, platelets &gt;50,000/mm<sup>3</sup>) in 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30801473','lexi-content-ref-Arnold.1','lexi-content-ref-21325604','lexi-content-ref-31794604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30801473','lexi-content-ref-Arnold.1','lexi-content-ref-21325604','lexi-content-ref-31794604'])">Ref</a></span>). <i>Alternative dosing:</i> 400 mg/kg once daily for 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Arnold.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Arnold.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Fetal and neonatal alloimmune thrombocytopenia (maternal administration):</i> IV:</b> 1 to 2 g/kg per week, with or without glucocorticoids (doses &gt;1 g/kg are typically divided into 2 doses and given over 2 days). Dose is dependent upon gestational age and risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30801473','lexi-content-ref-22015886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30801473','lexi-content-ref-22015886'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aea734cc-911f-4879-81a3-a23422745359">Lambert-Eaton myasthenic syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lambert-Eaton myasthenic syndrome (off-label use): IV: </b>2 g/kg administered in divided doses over 2 to 5 consecutive days (eg, 400 mg/kg once daily for 5 days) (maximum total daily dose: 1 g/kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22454268','lexi-content-ref-8797464','lexi-content-ref-9149073','lexi-content-ref-9140371']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22454268','lexi-content-ref-8797464','lexi-content-ref-9149073','lexi-content-ref-9140371'])">Ref</a></span>). For patients who respond to initial therapy, IVIG may be repeated every 4 to 12 weeks for symptom recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Weinberg.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Weinberg.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24cab06c-1510-44a6-9f5b-d28641decef8">Multifocal motor neuropathy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multifocal motor neuropathy: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial:</i>
<b> IV:</b> 2 g/kg administered in divided doses over 2 to 5 consecutive days (eg, 400 mg/kg once daily for 5 days) (maximum total daily dose: 1 g/kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21199100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21199100'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance: </i>
<b>Note: </b>Dosing is individualized and based on clinical response.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 1 to 2 g/kg every 2 to 6 weeks. If initial dose was administered over 5 days and was well tolerated, maintenance dose may be administered over a shorter duration (eg, total dose of 2 g/kg administered as 1 g/kg daily for 2 consecutive days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21199100','lexi-content-ref-Lange.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21199100','lexi-content-ref-Lange.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="832a6597-db9e-4ccb-bec7-44f39fa581e2">Myasthenia gravis, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myasthenia gravis, acute exacerbation (off-label use):</b>
<b>IV: </b>2 g/kg per treatment course, administered in divided doses over 2 to 5 consecutive days (eg, 400 mg/kg once daily for 5 days or 1 g/kg once daily for 2 days) (maximum total daily dose: 1 g/kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21562253','lexi-content-ref-17397768','lexi-content-ref-17353471']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21562253','lexi-content-ref-17397768','lexi-content-ref-17353471'])">Ref</a></span>). <b>Note:</b> A single dose of 1 g/kg may have similar efficacy to 1 g/kg given on 2 consecutive days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16286541']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16286541'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Myasthenia gravis, immune checkpoint inhibitor-induced, grade 3 or 4: </i>Note:</b> Initiate treatment early in the course of illness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28495807']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28495807'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 400 mg/kg once daily for 5 days (as an add-on to corticosteroid therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cbd41444-146e-4a07-8668-7272d9040f03">Parvovirus B19 infection, treatment, immunocompromised host</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parvovirus B19 infection, treatment, immunocompromised host (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Solid organ transplant:</i> IV:</b> 400 mg/kg once daily for 5 days in combination with a reduction of immunosuppression, if possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30973192']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30973192'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Patients with HIV: </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Optimal dose not well-defined.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial:</i>
<b> IV:</b> 400 mg/kg once daily for 5 to 10 days or 1 g/kg once daily for 2 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2173460','lexi-content-ref-1546732','lexi-content-ref-12240888']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2173460','lexi-content-ref-1546732','lexi-content-ref-12240888'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance</i>: <b>Note:</b> For patients with a CD4 count &lt;100 cells/mm<sup>3 </sup>to prevent relapse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Jordan.1','lexi-content-ref-10331506','lexi-content-ref-12240888']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Jordan.1','lexi-content-ref-10331506','lexi-content-ref-12240888'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 400 mg/kg once every 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2173460','lexi-content-ref-12240888']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2173460','lexi-content-ref-12240888'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1bd42a1b-f978-4a80-8eb2-03897489fa41">Pemphigus foliaceus and vulgaris, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pemphigus foliaceus and vulgaris, refractory (off-label use): IV:</b> 2 g/kg administered in divided doses over 2 to 5 consecutive days (eg, 400 mg/kg once daily for 5 days) every 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19293008','lexi-content-ref-18423257','lexi-content-ref-32830877','lexi-content-ref-15040478','lexi-content-ref-29438767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19293008','lexi-content-ref-18423257','lexi-content-ref-32830877','lexi-content-ref-15040478','lexi-content-ref-29438767'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b1e1e15-e17b-43d4-a03e-5f760312e129">Solid organ transplant desensitization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Solid organ transplant desensitization (adjunctive) (off-label use): Note: </b>Optimal dose, frequency, duration, and concomitant therapies are unknown and vary based on institutional protocols. These are example regimens for ABO-compatible transplants only; dosing is center and regimen dependent.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Heart transplant:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Standard dose:</i>
<b> IV:</b> 2 <b>g</b>/kg divided over 4 days; administered monthly for 1 to 3 months, as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10567309','lexi-content-ref-19285611','lexi-content-ref-29452978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10567309','lexi-content-ref-19285611','lexi-content-ref-29452978'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>High dose:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Use in patients who fail to have an adequate response to standard dose.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 3 <b>g</b>/kg divided over 4 days; administered monthly for 1 to 2 months, as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10567309','lexi-content-ref-29452978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10567309','lexi-content-ref-29452978'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Intestine transplant:</i></b>
<b>Note: </b>Check panel reactive antibody (PRA) 7 days after each IVIG dose with the goal of reducing PRA &lt;20% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16794543']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16794543'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 200 <b>mg</b>/kg every other week until transplant; if PRA remains &gt;20% after initial 2 doses, then increase dose to 500 <b>mg</b>/kg every other week for 2 doses; if PRA still remains &gt;20%, continue dose escalation along with additional therapies (eg, plasmapheresis, rituximab) until clinical end points are met; refer to protocol for additional details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16794543']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16794543'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Kidney</i>: IV: </b>2 <b>g</b>/kg (maximum: 180 <b>g</b>/dose) monthly for 4 doses prior to transplant; additional doses may be administered at 12 and 24 months if patient remains pretransplant; then 2 <b>g</b>/kg at the transplant and continued through the transplant surgery; and then 2 <b>g</b>/kg monthly for up to 4 months post-transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12973100','lexi-content-ref-15579530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12973100','lexi-content-ref-15579530'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f087d636-182c-4b12-9d94-3466357a24a7">Toxic shock syndrome, streptococcal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Toxic shock syndrome, streptococcal (adjunctive agent) (off-label use): IV: </b>1 g/kg on day 1, followed by 500 mg/kg once daily on days 2 and 3 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12884156','lexi-content-ref-29788397']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12884156','lexi-content-ref-29788397'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="992a0682-8a0f-4293-8ad0-146fa7ebf6a0">Warm autoimmune hemolytic anemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Warm autoimmune hemolytic anemia (adjunctive agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be used for patients who are improving but remain transfusion-dependent 2 weeks after starting first-line therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brugnara.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brugnara.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 500 mg/kg once daily for 4 days or 1 g/kg once daily for 2 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31412178','lexi-content-ref-Brugnara.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31412178','lexi-content-ref-Brugnara.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Switching from IV to SUBQ infusion dosing or switching between SUBQ products:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>S</i>
<i>witching from IV to SUBQ infusion dosing:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Cutaquig, Cuvitru:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>SUBQ infusion:</b> Begin treatment 1 week after patient's last IVIG dose.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Initial weekly dose (grams):</i> Divide the previous IVIG dose (grams) by the number of weeks between IV doses, then multiply this dose by 1.3 (dose adjustment factor).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Every-2-week dosing (grams): </i>Multiply the calculated weekly dose by 2.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Frequent (2 to 7 injections per week) dosing (grams):</i> Divide the calculated weekly dose by the desired number of injections per week.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">Gammagard Liquid, Gammaked, Gamunex-C:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>SUBQ infusion:</b> Begin 1 week after last IV dose. Use the following equation to calculate initial dose:</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Initial weekly dose (grams)</i> = [1.37 × previous IVIG dose (grams)] divided by [number of weeks between IV doses].</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">Hizentra:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>SUBQ infusion:</b> For weekly or frequent (up to daily) dosing, begin 1 week after last IVIG dose. For every-2-week dosing, begin 1 or 2 weeks after last IVIG dose. <b>Note:</b> Patient should have received IVIG routinely for at least 3 months before switching to SUBQ. Use the following equation to calculate initial weekly dose:</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Initial weekly dose (grams)</i> = [1.37 × previous IVIG dose (grams)] divided by [number of weeks between IV doses]. To convert the dose (in grams) to mL, multiply the calculated dose (in grams) by 5.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> Provided the total weekly dose is maintained, any dosing interval from daily up to every 2 weeks may be used. Use the following calculations to calculate frequent or every-2-week dosing:</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Every-2-week dosing (grams):</i> Multiply the calculated or previous weekly dose by 2.</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Frequent (2 to 7 injections per week) dosing (grams):</i> Divide the calculated or previous weekly dose by the desired number of injections per week.</p>
<p style="text-indent:-2em;margin-left:12em;">
<b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">HyQvia:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>SUBQ infusion:</b> For patients previously on another IVIG treatment, administer the first dose ~1 week after the last infusion of previous treatment.</p>
<p style="text-indent:-2em;margin-left:10em;">Administer the same dose and frequency as the previous IVIG treatment after the initial dose ramp-up. For subsequent dose adjustments, refer to product labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">Xembify:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>SUBQ infusion:</b> Begin treatment 1 week after patient's last IVIG dose.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Initial weekly dose (grams):</i> [1.37 × previous IVIG dose (grams)] divided by [number of weeks between IV doses].</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Frequent (2 to 7 injections per week) dosing (grams):</i> Divide the calculated weekly dose by the desired number of injections per week.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Switching between SUBQ products:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Cutaquig:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>SUBQ infusion:</b> Begin treatment 1 week after patient's last SUBQ immune globulin dose regardless of prior treatment regimen/frequency.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Initial weekly dose (grams):</i> Use the same dose as the prior SUBQ immune globulin treatment (grams).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Every-2-week dosing (grams): </i>Multiply the calculated weekly dose by 2.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Frequent (2 to 7 injections per week) dosing (grams):</i> Divide the calculated weekly dose by the desired number of administration injections per week.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">Cuvitru:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>SUBQ infusion: </b>Begin treatment 1 week after patient's last SUBQ immune globulin dose regardless of prior treatment regimen/frequency.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Weekly dosing (grams):</i> Weekly dose is the same as the prior immune globulin SUBQ weekly dose. If switching from HyQvia, divide the previous HyQvia dose (grams) by the number of weeks between HyQvia doses, then multiply this dose by 1.3 (dose adjustment factor).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Every-2-week dosing (grams): </i>Multiply the calculated weekly dose by 2.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Frequent (2 to 7 injections per week) dosing (grams):</i> Divide the calculated weekly dose by the desired number of administration injections per week.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">Hizentra:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>SUBQ infusion:</b> For weekly or frequent (up to daily) dosing, begin 1 week after last SUBQ infusion. For every-2-week dosing, begin 1 week after the last SUBQ weekly infusion. <b>Note:</b> Use the following equation to calculate initial weekly dose:</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Initial weekly dose:</i> Use previous weekly SUBQ dose initially.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> Provided the total weekly dose is maintained, any dosing interval from daily up to every 2 weeks may be used. Use the following conversions to calculate dosing:</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Every-2-week dosing (grams)</i>: Multiply the calculated or previous weekly dose by 2.</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Frequent (2 to 7 injections per week) dosing (grams):</i> Divide the calculated or previous weekly dose by the desired number of injections per week.</p>
<p style="text-indent:-2em;margin-left:12em;">
<b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">HyQvia:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>SUBQ infusion:</b> Begin treatment 1 week after patient's last infusion of their previous treatment regardless of prior treatment regimen/frequency.</p>
<p style="text-indent:-2em;margin-left:10em;">See manufacturer's labeling for initial ramp-up schedule (initiating treatment with a full monthly dose has not been evaluated).</p>
<p style="text-indent:-2em;margin-left:6em;">Xembify:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>SUBQ infusion:</b> Weekly dose is the same as the prior immune globulin SUBQ weekly dose (grams).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991441"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Use with caution due to risk of immune globulin-induced renal dysfunction; the rate of infusion and concentration of solution should be minimized. Discontinue if renal function deteriorates during treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">IM: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">SUBQ infusion: There are no dosage adjustments provided in the manufacturer's labeling; consider lower, more frequent dosing.</p></div>
<div class="block doha drugH1Div" id="F50988743"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">IM, IV, SUBQ infusion: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F11513249"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse effects are reported as class effects rather than for specific products in adult and pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, decreased heart rate, hypertension, hypotension, increased heart rate, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis, ecchymoses, injection site pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, diarrhea, nausea, upper abdominal pain, viral gastroenteritis, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, hemolysis, positive direct Coombs test</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum bilirubin (increased direct serum bilirubin or increased indirect serum bilirubin)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Bruising at injection site, erythema at injection site, injection site nodule, irritation at injection site, pain at injection site, swelling at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, dizziness, fatigue, headache, increased body temperature, pain, rigors</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular and skeletal: Asthenia, back pain, limb pain, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma, bronchitis, cough, epistaxis, nasal congestion, nasopharyngitis, pharyngitis, rhinitis, sinusitis (including acute sinusitis), upper respiratory tract infection, wheezing</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort, flushing, heart murmur, peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic dermatitis, eczema, erythema of skin, hyperhidrosis, pruritus, skin rash, urticaria, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration, increased lactate dehydrogenase, thyroiditis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention, aphthous stomatitis, dyspepsia, flatulence, gastritis, stomach discomfort</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis, dysuria, urinary tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise, hematoma, hemolytic anemia, leukopenia, neutropenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza, viral infection</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Induration at injection site, inflammation at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression, falling, fibromyalgia syndrome (exacerbation), hypertonia, lethargy, malaise, migraine, myasthenia, sensation of cold, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, joint effusion, joint swelling, muscle spasm, musculoskeletal pain, neck pain</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, flu-like symptoms, oropharyngeal pain, pharyngolaryngeal pain, pneumonia, viral upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Transient ischemic attacks</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Subcutaneous abscess</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, aseptic meningitis, chronic inflammatory demyelinating polyneuropathy (exacerbation)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrolithiasis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Facial flushing, thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis, diaphoresis, localized erythema, papule of skin, urticaria at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proximal tubular nephropathy</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Exacerbation of autoimmune pure red cell aplasia, hyperproteinemia, increased serum immunoglobulins (hyperviscosity), local hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Hematoma at injection site, local irritation, residual mass at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lower limb cramp</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine, renal tubular necrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchopneumonia, non-cardiogenic pulmonary edema</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, angina pectoris, arterial thrombosis, bradycardia, cerebrovascular accident, circulatory shock, deep vein thrombosis, edema, facial edema, hot and cold flashes, oxygen saturation decreased, palpitations, peripheral vascular insufficiency, phlebitis, pulmonary embolism, syncope, thromboembolism, thrombophlebitis, venous thrombosis (retinal vein thrombosis)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, bullous dermatitis, epidermolysis, erythema multiforme, erythematous rash, exfoliation of skin, pallor, rash at injection site, skin discoloration, skin ulceration at injection site, Stevens-Johnson syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased haptoglobins, hypervolemia, hyponatremia (Daphnis 2007; Nguyen 2006; Steinberger 2003), pseudohyponatremia (Daphnis 2007; Nguyen 2006; Steinberger 2003), translocational hyponatremia (Daphnis 2007; Nguyen 2006; Steinberger 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Oral paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria, hemoglobinuria, osmotic nephrosis, urine discoloration</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Acute intravascular hemolysis, decreased neutrophils, disseminated intravascular coagulation, increased hemoglobin, lymphadenopathy, pancytopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic insufficiency, hepatitis (noninfectious)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis, angioedema, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Tissue necrosis at injection site, warm sensation at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, burning sensation, coma, confusion, hypoesthesia, loss of consciousness, nervousness, paresthesia, restlessness, seizure, speech disturbance, voice disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Laryngospasm, muscle rigidity, polymyositis, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye pain, photophobia, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury, renal failure syndrome, renal insufficiency, renal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory distress syndrome, apnea, bronchospasm, cyanosis, hyperventilation, hypoxemia, hypoxia, pharyngeal edema, pulmonary edema, respiratory failure, transfusion-related acute lung injury</p></div>
<div class="block coi drugH1Div" id="F11513246"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to immune globulin or any component of the formulation; IgA deficiency (with anti-IgA antibodies and history of hypersensitivity [excluding Gammagard S/D]); hyperprolinemia (Hizentra, Privigen); hypersensitivity to corn (Octagam 5%); hereditary intolerance to fructose (Gammaplex 5%); infants/neonates for whom sucrose or fructose tolerance has not been established (Gammaplex 5%); hypersensitivity to hyaluronidase, human albumin, or any component of the hyaluronidase formulation (HyQvia).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): GamaSTAN S/D: Severe thrombocytopenia or coagulation disorders where IM injections are contraindicated.</p></div>
<div class="block war drugH1Div" id="F11513247"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur (some severe); patients with known antibodies to IgA are at greater risk; a severe fall in blood pressure may rarely occur with anaphylactic reaction; discontinue therapy and institute immediate treatment (including epinephrine 1 mg/mL) should be available.</p>
<p style="text-indent:-2em;margin-left:4em;">• Aseptic meningitis: Aseptic meningitis syndrome (AMS) has been reported with immune globulin administration; may occur with high doses (≥1 g/kg) and/or rapid infusion. Syndrome usually appears within several hours to 2 days following treatment; usually resolves within several days after product is discontinued. Female patients or patients with a migraine history may be at higher risk for AMS.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematoma: Do not administer subcutaneously for the treatment of immune thrombocytopenia because of the risk of hematoma formation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemolysis: Intravenous immune globulin has been associated with antiglobulin hemolysis (acute or delayed). Cases of hemolysis-related renal impairment/failure or disseminated intravascular coagulation have been reported. Risk factors associated with hemolysis include high doses (≥2 g/kg) given either as a single administration or divided over several days, underlying associated inflammatory conditions, and non-O blood type (FDA 2012). An underlying inflammatory state (eg, elevated C-reactive protein or erythrocyte sedimentation rate) may also increase the risk. Closely monitor patients for signs of hemolytic anemia, particularly in patients with preexisting anemia and/or cardiovascular or pulmonary compromise.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hereditary fructose intolerance: Immune globulin may contain sorbitol. The presence of sorbitol presents a risk to those with hereditary fructose intolerance (HFI). The incidence of HFI is estimated at 1 in 20,000 births and is usually diagnosed at the time of weaning when fructose or sucrose is introduced into the diet. Clinical symptoms include recurrent vomiting, abdominal pain, and hypoglycemia. Immune globulin containing sorbitol must not be administered to patients with HFI.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperproteinemia: Hyperproteinemia, increased serum viscosity, and hyponatremia may occur; distinguish hyponatremia from pseudohyponatremia to prevent volume depletion, a further increase in serum viscosity and a higher risk of thrombotic events.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertension: Elevations of blood pressure (systolic ≥180 mm Hg and/or diastolic &gt;120 mm Hg) have been observed during and/or shortly following infusion of Panzyga and Privigen, which resolved with either observation or changes in oral antihypertensive therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Patients should be monitored for adverse events during and after the infusion. Stop administration with signs of infusion reaction (fever, chills, nausea, vomiting, and rarely shock). Risk may be increased with initial treatment, when switching brands of immune globulin, and with treatment interruptions of &gt;8 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary edema: Monitor for transfusion-related acute lung injury (TRALI); noncardiogenic pulmonary edema has been reported with immune globulin use. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, and fever in the presence of normal left ventricular function. Usually occurs within 1 to 6 hours after infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal dysfunction and acute renal failure: <b>[US Boxed Warning]: IV administration only: Acute renal dysfunction (increased serum creatinine, oliguria, acute renal failure, osmotic nephrosis) can rarely occur and has been associated with fatalities</b>
<b>in predisposed patients. Patients predisposed to renal dysfunction include elderly patients, patients with renal disease, diabetes mellitus, hypovolemia, volume depletion, sepsis, paraproteinemia, and nephrotoxic medications due to risk of renal dysfunction.</b>
<b>Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose.</b> (<b>Note:</b> The following IV products do not contain sucrose: Asceniv, Bivigam, Flebogamma DIF, Gammagard Liquid, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam 5%, Octagam 10%, Panzyga, and Privigen). <b>In patients at risk of renal dysfunction or acute renal failure, ensure adequate hydration prior to administration; the dose, rate of infusion, and concentration of solution should be minimized. </b>Assess renal function prior to treatment and periodically thereafter. Discontinue if renal function deteriorates.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic events: <b>[US Boxed Warning]: Thrombosis may occur with immune globulin products even in the absence of risk factors for thrombosis. For patients at risk of thrombosis (eg, advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors), administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity,</b> such as those with cryoglobulins, fasting chylomicronemia/severe hypertriglyceridemia, or monoclonal gammopathies.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fluid overload: High-dose regimens (1 g/kg for 1 to 2 days) are not recommended for individuals with fluid overload or where fluid volume may be of concern.</p>
<p style="text-indent:-2em;margin-left:4em;">• IgA deficiency: Increased risk of hypersensitivity, especially in patients with anti-IgA antibodies; use is contraindicated in patients with IgA deficiency (with antibodies against IgA and history of hypersensitivity) or isolated IgA deficiency (GamaSTAN S/D [Canadian product]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution; ensure adequate hydration prior to administration; the rate of infusion and concentration of solution should be minimized.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in elderly patients; may be at increased risk for renal dysfunction/failure and thromboembolic events.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Human plasma: Product of human plasma; may potentially contain infectious agents (eg, viruses, the variant Creutzfeldt Jakob disease [vCJD] agent and, theoretically, the Creutzfeldt Jakob disease [CJD] agent) that could transmit disease, including unknown or emerging viruses and other pathogens. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>
<p style="text-indent:-2em;margin-left:4em;">• L-proline: Hizentra and Privigen contain the stabilizer L-proline and are contraindicated in patients with hyperprolinemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Maltose: Some products may contain maltose, which may result in falsely elevated blood glucose readings. Maltose-containing products may be contraindicated with patients with corn allergy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin testing: Skin testing should not be performed with GamaSTAN or GamaSTAN S/D [Canadian product] as local irritation can occur and be misinterpreted as a positive reaction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium: Some products may contain sodium.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sorbitol: Some products may contain sorbitol; do not use immune globulin in patients with hereditary fructose intolerance.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sucrose: Some products may contain sucrose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Do not infuse into or around an infected area due to the risk of spreading a localized infection.</p>
<p style="text-indent:-2em;margin-left:4em;">• High-dose regimen: Consider risk versus benefit for high-dose regimen in patients with increased risk of thrombosis, hemolysis, acute kidney injury, or volume overload.</p></div>
<div class="block prod-avail drugH1Div" id="F58955700"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Alyglo (10% immune globulin): FDA approved December 2023; availability anticipated in mid-2024. Information pertaining to this product within the monograph is pending revision. Alyglo is indicated for the treatment of primary humoral immunodeficiency in patients 17 years of age and older. Consult the prescribing information for additional information.</p></div>
<div class="block dosfc drugH1Div" id="F26116456"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Carimune NF may contain a significant amount of sodium and also contains sucrose.</p>
<p style="text-indent:-2em;margin-left:2em;">Cutaquig contains maltose.</p>
<p style="text-indent:-2em;margin-left:2em;">Gammagard S/D may contain a significant amount of sodium and also contains glucose.</p>
<p style="text-indent:-2em;margin-left:2em;">Octagam contains maltose.</p>
<p style="text-indent:-2em;margin-left:2em;">Hyqvia Kit is supplied with a Hyaluronidase (Human Recombinant) component intended for injection prior to Immune Globulin administration to improve dispersion and absorption of the Immune Globulin.</p></div>
<div class="block foc drugH1Div" id="F11513299"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Injectable, Intramuscular [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GamaSTAN: 15% to 18% [150 to 180 mg/mL] (2 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hyqvia: 10 g immune globulin (human)/100 mL with an 800 unit hyaluronidase vial, 5 g immune globulin (human)/50 mL with a 400 unit hyaluronidase vial, 2.5 g immune globulin (human)/25 mL with a 200 unit hyaluronidase vial, 20 g immune globulin (human)/200 mL with a 1,600 unit hyaluronidase vial, 30 g immune globulin (human)/300 mL with a 2,400 unit hyaluronidase vial [contains albumin human, edetate (edta) disodium dihydrate]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gammagard: 1 g/10 mL (10 mL); 2.5 g/25 mL (25 mL); 5 g/50 mL (50 mL); 10 g/100 mL (100 mL); 20 g/200 mL (200 mL); 30 g/300 mL (300 mL) [latex free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gammaked: 1 g/10 mL (10 mL); 5 g/50 mL (50 mL); 10 g/100 mL (100 mL); 20 g/200 mL (200 mL) [latex free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gamunex-C: 1 g/10 mL (10 mL); 2.5 g/25 mL (25 mL); 5 g/50 mL (50 mL); 10 g/100 mL (100 mL); 20 g/200 mL (200 mL); 40 g/400 mL (400 mL) [latex free]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Asceniv: 5 g/50 mL (50 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bivigam: 10 g/100 mL (100 mL) [latex free, sugar free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bivigam: 5 g/50 mL (50 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bivigam: 5 g/50 mL (50 mL [DSC]) [sugar free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Flebogamma DIF: 0.5 g/10 mL (10 mL); 5 g/50 mL (50 mL [DSC]); 5 g/100 mL (100 mL); 10 g/100 mL (100 mL [DSC]); 20 g/200 mL (200 mL [DSC]); 20 g/400 mL (400 mL); 10 g/200 mL (200 mL); 2.5 g/50 mL (50 mL [DSC]) [contains polyethylene glycol (macrogol)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gammaplex: 5 g/50 mL (50 mL); 5 g/100 mL (100 mL); 10 g/100 mL (100 mL); 20 g/200 mL (200 mL); 20 g/400 mL (400 mL); 10 g/200 mL (200 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Octagam: 1 g/20 mL (20 mL); 2 g/20 mL (20 mL); 5 g/50 mL (50 mL); 5 g/100 mL (100 mL); 10 g/100 mL (100 mL); 20 g/200 mL (200 mL); 30 g/300 mL (300 mL); 10 g/200 mL (200 mL); 2.5 g/50 mL (50 mL) [latex free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Octagam: 1 g/20 mL (20 mL); 2 g/20 mL (20 mL); 5 g/50 mL (50 mL); 5 g/100 mL (100 mL); 10 g/100 mL (100 mL); 20 g/200 mL (200 mL); 25 g/500 mL (500 mL [DSC]); 30 g/300 mL (300 mL); 10 g/200 mL (200 mL); 2.5 g/50 mL (50 mL) [sucrose free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Panzyga: Immune globulin (human)-ifas 1 g/10mL (10 mL); Immune globulin (human)-ifas 30 g/300 mL (300 mL); Immune globulin (human)-ifas 20 g/200 mL (200 mL); Immune globulin (human)-ifas 2.5 g/25 mL (25 mL); Immune globulin (human)-ifas 10 g/100 mL (100 mL); Immune globulin (human)-ifas 5 g/50 mL (50 mL) [latex free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Panzyga: Immune globulin (human)-ifas 1 g/10mL (10 mL); Immune globulin (human)-ifas 5 g/50 mL (50 mL); Immune globulin (human)-ifas 10 g/100 mL (100 mL); Immune globulin (human)-ifas 2.5 g/25 mL (25 mL); Immune globulin (human)-ifas 20 g/200 mL (200 mL); Immune globulin (human)-ifas 30 g/300 mL (300 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Privigen: 5 g/50 mL (50 mL); 10 g/100 mL (100 mL); 20 g/200 mL (200 mL); 40 g/400 mL (400 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cutaquig: 1 g/6 mL (6 mL); 1.65 g/10 mL (10 mL); 2 g/12 mL (12 mL); 3.3 g/20 mL (20 mL); 4 g/24 mL (24 mL); 8 g/48 mL (48 mL) [latex free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cuvitru: 1 g/5 mL (5 mL); 2 g/10 mL (10 mL); 4 g/20 mL (20 mL); 8 g/40 mL (40 mL); 10 g/50 mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hizentra: 1 g/5 mL (5 mL); 2 g/10 mL (10 mL); 4 g/20 mL (20 mL); 10 g/50 mL (50 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xembify: Immune globulin (human)-klhw 1 g/5 mL (5 mL); Immune globulin (human)-klhw 2 g/10 mL (10 mL); Immune globulin (human)-klhw 4 g/20 mL (20 mL); Immune globulin (human)-klhw 10 g/50 mL (50 mL) [latex free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hizentra: 1 g/5 mL (5 mL); 2 g/10 mL (10 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hizentra: 4 g/20 mL (20 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carimune NF: 6 g (1 ea [DSC]); 12 g (1 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gammagard S/D Less IgA: 5 g (1 ea); 10 g (1 ea) [contains albumin human, polyethylene glycol (macrogol), polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F11513236"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322887"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Hyqvia Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 g/25 mL (per mL): $27.32</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 gm/50 mL (per mL): $27.32</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 g/100 mL (per mL): $27.32</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 g/200 mL (per mL): $27.32</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 g/300 mL (per mL): $27.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Asceniv Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 gm/50 mL (per mL): $111.26</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Bivigam Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 gm/50 mL (per mL): $17.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 g/100 mL (per mL): $17.02</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Cutaquig Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1GM/6ML (per mL): $38.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.65 g/10 mL (per mL): $38.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2GM/12ML (per mL): $38.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.3 g/20 mL (per mL): $38.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4GM/24ML (per mL): $38.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8GM/48ML (per mL): $38.87</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Cuvitru Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/5 mL (per mL): $53.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g/10 mL (per mL): $53.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 g/20 mL (per mL): $53.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 g/40mL (per mL): $53.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 gm/50 mL (per mL): $53.87</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Flebogamma DIF Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 g/10 mL (per mL): $6.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 g/100 mL (per mL): $6.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 g/200 mL (per mL): $6.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 g/400 mL (per mL): $6.35</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Gammagard Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/10 mL (per mL): $20.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 g/25 mL (per mL): $20.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 gm/50 mL (per mL): $20.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 g/100 mL (per mL): $20.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 g/200 mL (per mL): $20.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 g/300 mL (per mL): $20.34</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Gammaked Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/10 mL (per mL): $23.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 gm/50 mL (per mL): $23.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 g/100 mL (per mL): $23.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 g/200 mL (per mL): $23.55</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Gammaplex Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 g/100 mL (per mL): $12.33</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 gm/50 mL (per mL): $24.65</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 g/100 mL (per mL): $24.65</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 g/200 mL (per mL): $12.33</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 g/200 mL (per mL): $24.65</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 g/400 mL (per mL): $12.33</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Gamunex-C Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/10 mL (per mL): $16.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 g/25 mL (per mL): $16.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 gm/50 mL (per mL): $16.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 g/100 mL (per mL): $16.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 g/200 mL (per mL): $16.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 g/400 mL (per mL): $16.76</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Hizentra Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/5 mL (per mL): $52.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g/10 mL (per mL): $52.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 g/20 mL (per mL): $52.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 gm/50 mL (per mL): $52.78</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Octagam Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/20 mL (per mL): $11.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g/20 mL (per mL): $23.31</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 gm/50 mL (per mL): $11.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 g/100 mL (per mL): $11.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 gm/50 mL (per mL): $23.31</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 g/100 mL (per mL): $23.31</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 g/200 mL (per mL): $11.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 g/200 mL (per mL): $23.31</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 g/300 mL (per mL): $23.31</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Panzyga Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/10 mL (per mL): $23.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 g/25 mL (per mL): $23.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 gm/50 mL (per mL): $23.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 g/100 mL (per mL): $23.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 g/200 mL (per mL): $23.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 g/300 mL (per mL): $23.86</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Privigen Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 gm/50 mL (per mL): $21.11</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 g/100 mL (per mL): $21.11</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 g/200 mL (per mL): $21.11</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 g/400 mL (per mL): $21.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Xembify Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/5 mL (per mL): $43.13</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g/10 mL (per mL): $43.13</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 g/20 mL (per mL): $43.13</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 gm/50 mL (per mL): $43.13</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Gammagard S/D Less IgA Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 g (per each): $1,345.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 g (per each): $2,691.12</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Hizentra Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/5 mL (per mL): $52.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g/10 mL (per mL): $52.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 g/20 mL (per mL): $52.78</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871251"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Injectable, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gamastan S/D: 15% to 18% [150 to 180 mg/mL] ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hyqvia: 10 g immune globulin (human)/100 mL with an 800 unit hyaluronidase vial, 5 g immune globulin (human)/50 mL with a 400 unit hyaluronidase vial, 2.5 g immune globulin (human)/25 mL with a 200 unit hyaluronidase vial, 20 g immune globulin (human)/200 mL with a 1,600 unit hyaluronidase vial, 30 g immune globulin (human)/300 mL with a 2,400 unit hyaluronidase vial [contains albumin human, edetate (edta) disodium dihydrate]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gammagard: 10% (10 mL, 25 mL, 50 mL, 100 mL, 200 mL, 300 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gamunex: 10% (25 mL, 50 mL, 100 mL, 200 mL, 400 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Octagam: 5% (50 mL, 100 mL, 200 mL); 10% (20 mL, 50 mL, 100 mL, 200 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Panzyga: 100 mg/mL (10 mL, 25 mL, 50 mL, 100 mL, 200 mL, 300 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Privigen: 10% (25 mL, 50 mL, 100 mL, 200 mL, 400 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cutaquig: 165 mg/mL (6 mL, 12 mL, 24 mL, 48 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hizentra: 200 mg/mL (5 mL, 10 mL, 15 mL, 20 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg/mL (5 mL, 10 mL, 20 mL, 40 mL, 50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hizentra: 4 g/20 mL (20 mL) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gammagard S/D: 5 g (1 ea); 10 g (1 ea) [contains albumin human, polyethylene glycol (macrogol), polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">IGIVnex: 10 g (10 mL, 25 mL, 50 mL, 100 mL, 200 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Iveegam Immuno: 1 g (1 ea); 7.5 g (1 ea); 10 g (1 ea)</p></div>
<div class="block adip drugH1Div" id="F53569468"><span class="drugH1">Additional Information</span>
<p style="text-indent:-2em;margin-left:2em;">IM: When administering immune globulin for hepatitis A prophylaxis, use should be considered for the following close contacts of persons with confirmed hepatitis A: Unvaccinated household and sexual contacts, persons who have shared illicit drugs, regular babysitters, staff and attendees of child care centers, food handlers within the same establishment (CDC 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">DIF: Dual inactivation plus nanofiltration.</p>
<p style="text-indent:-2em;margin-left:2em;">NF: Nanofiltered.</p>
<p style="text-indent:-2em;margin-left:2em;">S/D: Solvent detergent treated.</p>
<p style="text-indent:-2em;margin-left:2em;">Octagam contains sodium 30 mmol/L.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IgA content:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Asceniv: ≤200 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">Bivigam: ≤200 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">Carimune NF: Manufacturer's labeling: Trace amounts; others have reported 1,000 to 2,000 mcg/mL in a 6% solution (Siegel 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">Cutaquig: ≤600 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">Cuvitru: Average 80 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">Flebogamma 5% DIF: &lt;50 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">Flebogamma 10% DIF: &lt;100 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">GamaSTAN: Not specified.</p>
<p style="text-indent:-2em;margin-left:4em;">Gammagard Liquid: Average 37 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">Gammagard S/D 5% solution: &lt;1 mcg/mL (see <b>Note</b>).</p>
<p style="text-indent:-2em;margin-left:4em;">Gammaked: Average 46 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">Gammaplex 5%: &lt;10 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">Gammaplex 10%: &lt;20 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">Gamunex-C: Average 46 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">Hizentra: ≤50 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">HyQvia: Average 37 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">Octagam 5%: ≤200 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">Octagam 10%: Average 106 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">Panzyga 10%: Average 100 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">Privigen: ≤25 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">Xembify: Not specified.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Manufacturer has discontinued Gammagard S/D 5% solution; however, the lower IgA product may be available by special request for patients with known reaction to IgA or IgA deficiency with antibodies.</p></div>
<div class="block admp drugH1Div" id="F52614235"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: <b>Note:</b> If plasmapheresis employed for treatment of condition, administer immune globulin after completion of plasmapheresis session.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Infuse over 2 to 24 hours with initial infusion administered slowly and titrated as tolerated; administer in separate infusion line from other medications; if using primary line, flush with NS or D5W (product specific; consult product prescribing information) prior to administration. Decrease dose, rate, and/or concentration of infusion in patients who may be at risk of renal failure. Decreasing the rate or stopping the infusion may help relieve some adverse effects (flushing, changes in pulse rate, changes in blood pressure). Epinephrine should be available during administration.</p>
<p style="text-indent:-2em;margin-left:4em;">For initial treatment, a lower concentration and/or a slower rate of infusion should be used. Initial rate of administration and titration is specific to each IVIG product. Refrigerated products should be warmed to room temperature prior to infusion. Some products require filtration; refer to individual product labeling. Antecubital veins should be used, especially with concentrations ≥10% to prevent injection site discomfort.</p>
<p style="text-indent:-2em;margin-left:6em;">Asceniv 10%: Primary humoral immunodeficiency: Initial (first 15 minutes): 0.5 mg/kg/minute (0.3 <b>mL</b>/kg/<b>hour</b>); if tolerated, increase every 15 minutes up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:6em;">Bivigam 10%: Primary humoral immunodeficiency: Initial rate: 0.5 mg/kg/minute (0.3 <b>mL</b>/kg/<b>hour</b>) for 10 minutes; if tolerated, increase every 20 minutes by 0.8 mg/kg/minute (0.48 <b>mL</b>/kg/<b>hour</b>) up to 6 mg/kg/minute (3.6 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:6em;">Carimune NF: Primary humoral immunodeficiency or immune thrombocytopenia: Initial rate: 0.5 mg/kg/minute for 30 minutes; if tolerated, increase to 1 mg/kg/minute, if tolerated after 30 minutes, may increase gradually up to 3 mg/kg/minute; rate in mL/kg/hour varies based on concentration; refer to product labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">Flebogamma DIF 5%: Primary humoral immunodeficiency: Initial rate: 0.5 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>) for the first 30 minutes; if tolerated, increase slowly up to 5 mg/kg/minute (6 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:6em;">Flebogamma DIF 10%: Primary humoral immunodeficiency or immune thrombocytopenia: Initial rate: 1 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>) for first 30 minutes; if tolerated, increase slowly up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:6em;">Gammagard Liquid 10%: Primary humoral immunodeficiency: Initial rate: 0.8 mg/kg/minute (0.5 <b>mL</b>/kg/<b>hour</b>) for 30 minutes; if tolerated, increase every 30 minutes up to 8 mg/kg/minute (5 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:6em;">Gammagard S/D: 5% solution: Initial rate: 0.5 <b>mL</b>/kg/<b>hour</b>; if tolerated, may increase to a maximum rate of 4 <b>mL</b>/kg/<b>hour</b>. If 5% solution is tolerated at maximum rate, may administer 10% solution with an initial rate of 0.5 <b>mL</b>/kg/<b>hour</b>; if tolerated, may increase to a maximum rate of 8 <b>mL</b>/kg/<b>hour</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Gammaked 10%:</p>
<p style="text-indent:-2em;margin-left:8em;">CIDP: Initial rate: 2 mg/kg/minute (1.2 <b>mL</b>/kg/<b>hour</b>) for 30 minutes; if tolerated, increase gradually up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:8em;">Primary humoral immunodeficiency or ITP: Initial rate: 1 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>) for 30 minutes; if tolerated, increase gradually up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:6em;">Gammaplex 5%: Primary humoral immunodeficiency or ITP: Initial rate: 0.5 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>) for 15 minutes; if tolerated, increase every 15 minutes up to 4 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:6em;">Gammaplex 10%: Primary humoral immunodeficiency or ITP: Initial rate: 0.5 mg/kg/minute (0.3 <b>mL</b>/kg/<b>hour</b>) for 15 minutes; if tolerated, increase every 15 minutes up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:6em;">Gamunex-C 10%:</p>
<p style="text-indent:-2em;margin-left:8em;">CIDP: Initial rate: 2 mg/kg/minute (1.2 <b>mL</b>/kg/<b>hour</b>) for 30 minutes; if tolerated, increase gradually up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:8em;">Primary humoral immunodeficiency or ITP: Initial rate: 1 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>) for 30 minutes; if tolerated, increase gradually up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:6em;">Octagam 5%: Primary humoral immunodeficiency: Initial rate: 0.5 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>) for 30 minutes; if tolerated, double the infusion rate every 30 minutes up to a maximum rate of &lt;3.33 mg/kg/minute (4.2 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:6em;">Panzyga 10%: Primary humoral immunodeficiency: Initial (first 30 minutes): 1 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>); if tolerated, increase gradually every 15 to 30 minutes up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>) in treatment-naive patients or if it has been &gt;8 weeks since last infusion <b>or</b> up to 12 to 14 mg/kg/minute (7.2 to 8.4 <b>mL</b>/kg/<b>hour</b>) in treatment-experienced patients.</p>
<p style="text-indent:-2em;margin-left:6em;">Privigen 10%:</p>
<p style="text-indent:-2em;margin-left:8em;">ITP: Initial rate: 0.5 mg/kg/minute (0.3 <b>mL</b>/kg/<b>hour</b>); if tolerated, increase gradually up to 4 mg/kg/minute (2.4 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:8em;">Primary humoral immunodeficiency: Initial rate: 0.5 mg/kg/minute (0.3 <b>mL</b>/kg/<b>hour</b>); if tolerated, increase gradually up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:8em;">CIDP: Initial rate: 0.5 mg/kg/minute (0.3 <b>mL</b>/kg/<b>hour</b>); if tolerated, increase gradually up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:2em;">IM: Administer IM in the anterolateral aspects of the upper thigh or deltoid muscle of the upper arm. Avoid gluteal region due to risk of injury to sciatic nerve. Divide doses &gt;10 mL (adult) and inject in multiple sites; in pediatric patients, consider splitting doses &lt;10 mL based on patient size.</p>
<p style="text-indent:-2em;margin-left:2em;">SUBQ infusion: Initial dose should be administered in a health care setting capable of providing monitoring and treatment in the event of hypersensitivity. Using aseptic technique, follow the infusion device manufacturer's instructions for filling the reservoir and preparing the pump. Remove air from administration set and needle by priming. Dose may be infused into multiple sites simultaneously. After administration sites are clean and dry, insert subcutaneous needle and prime administration set. Attach sterile needle to administration set, gently pull back on the syringe to assure a blood vessel has not been inadvertently accessed; if blood is present, remove and discard needle and tubing; repeat process using a new needle and tubing and different injection site. Repeat for each injection site; deliver the dose following instructions for the infusion device. Rotate the site(s) between successive infusions. Treatment may be transitioned to the home/home care setting in the absence of adverse reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">Cutaquig:</p>
<p style="text-indent:-2em;margin-left:6em;">Injection sites: Abdomen, thigh, upper arm, and/or upper leg/hip area (avoid areas that are scarred, tattooed, injured, or inflamed); ≤6 simultaneous injection sites (spaced ≥2 inches apart).</p>
<p style="text-indent:-2em;margin-left:6em;">Recommended infusion rate:</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥2 years and Adolescents &lt;18 years: First 2 infusions: ≤15 mL/hour per injection site; subsequent infusions: Gradually increase as tolerated by ~5 to 10 mL/hour per injection site every 2 to 4 weeks to maximum rate of 25 mL/hour per injection site.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents ≥18 years: First 2 infusions: ≤20 mL/hour per injection site; subsequent infusions: Gradually increase as tolerated by ~10 mL/hour per injection site every 2 to 4 weeks to a maximum rate of 52 mL/hour per injection site.</p>
<p style="text-indent:-2em;margin-left:6em;">Recommended infusion volume:</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥2 to 6 years: First 2 infusions: ≤10 mL per injection site; subsequent infusions: Gradually increase as tolerated by ~5 to 10 mL per infusion site every 2 to 4 weeks up to a maximum of 15.5 mL per injection site.</p>
<p style="text-indent:-2em;margin-left:8em;">Children &gt;6 years and Adolescents &lt;17 years: First 2 infusions: ≤15 mL per injection site; subsequent infusions: Gradually increase as tolerated by ~5 to 10 mL per infusion site every 2 to 4 weeks up to a maximum of 29 mL per injection site.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents ≥17 years: First 2 infusions: ≤25 mL per injection site; subsequent infusions: Gradually increase as tolerated by ~10 mL per infusion site every 2 to 4 weeks up to a maximum of 40 mL per site.</p>
<p style="text-indent:-2em;margin-left:4em;">Cuvitru: <b>Note: </b>It is recommended that infusion be complete within 2 hours of preparation.</p>
<p style="text-indent:-2em;margin-left:6em;">Injection sites: Abdomen, thighs, upper arms, or lateral hip (avoid bony areas, visible blood vessels, and areas that are scarred, inflamed, or infected); ≤4 simultaneous injection sites (spaced 4 inches apart or more).</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum infusion rate<b>: </b>10 to 20 mL/hour per injection site (first 2 infusions); may be increased to 60 mL/hour per injection site (as tolerated) for subsequent infusions.</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum infusion volume:</p>
<p style="text-indent:-2em;margin-left:8em;">Patients &lt;40 kg: 20 mL per injection site (first 2 infusions); may increase to 60 mL per site for subsequent infusions.</p>
<p style="text-indent:-2em;margin-left:8em;">Patients ≥40 kg: 60 mL per injection site.</p>
<p style="text-indent:-2em;margin-left:4em;">Gammagard Liquid:</p>
<p style="text-indent:-2em;margin-left:6em;">Injection sites: Abdomen, thighs, upper arms, or lower back (avoid bony areas, visible blood vessels, and areas that are scarred, inflamed, or infected); ≤8 simultaneous injection sites (spaced ≥2 inches apart).</p>
<p style="text-indent:-2em;margin-left:6em;">Recommended infusion rate:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;40 kg: Initial infusion: 15 mL/hour per injection site; subsequent infusions: 15 to 20 mL/hour per injection site; maximum: 160 mL/hour for all simultaneous sites combined.</p>
<p style="text-indent:-2em;margin-left:8em;">≥40 kg: Initial infusion: 20 mL/hour per injection site; subsequent infusions: 20 to 30 mL/hour per injection site; maximum: 240 mL/hour for all simultaneous sites combined.</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum infusion volume:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;40 kg: 20 mL per injection site.</p>
<p style="text-indent:-2em;margin-left:8em;">≥40 kg: 30 mL per injection site.</p>
<p style="text-indent:-2em;margin-left:4em;">Gammaked, Gamunex-C:</p>
<p style="text-indent:-2em;margin-left:6em;">Injection sites: Abdomen, thighs, upper arms, and/or lateral hip; ≤6 simultaneous injection sites (spaced ≥2 inches apart) (≤8 sites may be used in adults).</p>
<p style="text-indent:-2em;margin-left:6em;">Recommended infusion rate:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;25 kg: 10 mL/hour per infusion site.</p>
<p style="text-indent:-2em;margin-left:8em;">≥25 kg: Initial: 15 mL/hour per infusion site; may increase up to 20 mL/hour per infusion site.</p>
<p style="text-indent:-2em;margin-left:4em;">Hizentra:</p>
<p style="text-indent:-2em;margin-left:6em;">Injection sites: Abdomen, thigh, upper arm, and/or lateral hip (avoid scars, stretch marks, and areas that are tender, bruised, red, or hard); ≤8 simultaneous injection sites (spaced ≥2 inches apart).</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum infusion rate: First infusion: 15 mL/hour per injection site (primary humoral immunodeficiency) or 20 mL/hour per injection site (CIDP); subsequent infusions: 25 mL/hour per injection site (primary humoral immunodeficiency) or 50 mL/hour per injection site (CIDP).</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum infusion volume: First infusions: 15 mL per injection site (primary humoral immunodeficiency) or 20 mL per injection site (CIDP); subsequent infusions: 25 mL per injection site (primary humoral immunodeficiency) or 50 mL per injection site (CIDP).</p>
<p style="text-indent:-2em;margin-left:4em;">HyQvia: Administer the two components of HyQvia (immune globulin and hyaluronidase) sequentially, beginning with the hyaluronidase; do not use either component alone. Infusion pump capable of infusing rates up to 300 mL/hour/site required; must also have the ability to titrate the flow rate. Use a 24-gauge subcutaneous needle set labeled for high flow rates. Infusion site leakage can occur; consider using longer needles (14 mm or 12 mm) and/or more than one infusion site. Initiate the infusion of the full dose of the immune globulin through the same subcutaneous needle set within ~10 minutes of hyaluronidase infusion. For each full or partial vial of immune globulin used, administer the entire contents of the hyaluronidase vial. A second site can be used based on tolerability and total volume; if a second site is used, it should be placed on the opposite side of the body; administer half of total volume of the hyaluronidase in each site. Flush the infusion line with NS or D5W if required.</p>
<p style="text-indent:-2em;margin-left:6em;">Injection sites: Middle to upper abdomen or thigh (avoid bony prominences or areas that are scarred, inflamed, or infected).</p>
<p style="text-indent:-2em;margin-left:6em;">Volume per site:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;40 kg: ≤300 mL per injection site.</p>
<p style="text-indent:-2em;margin-left:8em;">≥40 kg: ≤600 mL per injection site.</p>
<p style="text-indent:-2em;margin-left:6em;">Infusion rate:</p>
<p style="text-indent:-2em;margin-left:8em;">Immune globulin:</p>
<p style="text-indent:-2em;margin-left:10em;">First 2 infusions:</p>
<p style="text-indent:-2em;margin-left:12em;">&lt;40 kg: 5 mL/hour for 5 to 15 minutes; 10 mL/hour for 5 to 15 minutes; 20 mL/hour for 5 to 15 minutes; 40 mL/hour for 5 to 15 minutes; then 80 mL/hour for remainder of infusion.</p>
<p style="text-indent:-2em;margin-left:12em;">≥40 kg: 10 mL/hour for 5 to 15 minutes; 30 mL/hour for 5 to 15 minutes; 60 mL/hour for 5 to 15 minutes; 120 mL/hour for 5 to 15 minutes; then 240 mL/hour for remainder of infusion.</p>
<p style="text-indent:-2em;margin-left:10em;">Next 2 or 3 infusions:</p>
<p style="text-indent:-2em;margin-left:12em;">&lt;40 kg: 10 mL/hour for 5 to 15 minutes; 20 mL/hour for 5 to 15 minutes; 40 mL/hour for 5 to 15 minutes; 80 mL/hour for 5 to 15 minutes; then 160 mL/hour for remainder of infusion.</p>
<p style="text-indent:-2em;margin-left:12em;">≥40 kg: 10 mL/hour for 5 to 15 minutes; 30 mL/hour for 5 to 15 minutes; 120 mL/hour for 5 to 15 minutes; 240 mL/hour for 5 to 15 minutes; then 300 mL/hour for remainder of infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">Xembify: <b>Note: </b>It is recommended that infusion be complete within 2 hours of preparation to avoid the potential formation of particles caused by siliconized syringes.</p>
<p style="text-indent:-2em;margin-left:6em;">Injection sites: Abdomen, thigh, upper arm, sides, back, and/or lateral hip (avoid bony prominence or areas that are scarred, inflamed, or infected); ≤6 simultaneous injection sites (spaced ≥2 inches apart).</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum infusion rate: 25 mL/hour per injection site.</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum infusion volume: 25 mL per injection site.</p></div>
<div class="block adm drugH1Div" id="F11513282"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> If plasmapheresis employed for treatment of condition, administer immune globulin <b>after</b> completion of plasmapheresis session.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Administer IM in the anterolateral aspects of the upper thigh or deltoid muscle of the upper arm. Avoid gluteal region due to risk of injury to sciatic nerve. Divide doses &gt;10 mL and inject in multiple sites.</p>
<p style="text-indent:-2em;margin-left:4em;">GamaSTAN and GamaSTAN S/D [Canadian product] are for IM administration only.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>IV infusion:</b> Infuse over 2 to 24 hours; administer in separate infusion line from other medications; if using primary line, flush with NS or D5W (product specific; consult product prescribing information) prior to administration. Decrease dose, rate and/or concentration of infusion in patients who may be at risk of renal failure. Decreasing the rate or stopping the infusion may help relieve some adverse effects (flushing, changes in pulse rate, changes in blood pressure). Epinephrine should be available during administration. For initial treatment or in elderly patients, a lower concentration and/or a slower rate of infusion should be used. Initial rate of administration and titration is specific to each IGIV product. Refrigerated product should be warmed to room temperature prior to infusion. Some products require filtration; refer to individual product labeling. Antecubital veins should be used, especially with concentrations ≥10% to prevent injection-site discomfort.</p>
<p style="text-indent:-2em;margin-left:4em;">Asceniv: Primary humoral immunodeficiency: Initial (first 15 minutes): 0.5 mg/kg/minute (0.3 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase every 15 minutes (if tolerated) up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:4em;">Bivigam 10%: Primary humoral immunodeficiency: Initial (first 10 minutes): 0.5 mg/kg/minute (0.3 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase every 20 minutes (if tolerated) by 0.8 mg/kg/minute (0.48 <b>mL</b>/kg/<b>hour)</b> up to 6 mg/kg/minute (3.6 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:4em;">Carimune NF: Refer to product labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">Flebogamma DIF 5%: Primary humoral immunodeficiency: Initial: 0.5 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase slowly (if tolerated) up to 5 mg/kg/minute (6 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:4em;">Flebogamma DIF 10%: Primary humoral immunodeficiency or immune thrombocytopenia: Initial: 1 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase slowly (if tolerated) up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:4em;">Gammagard Liquid 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Multifocal motor neuropathy: Initial: 0.8 mg/kg/minute (0.5 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase gradually (if tolerated) up to 9 mg/kg/minute (5.4 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:6em;">Primary humoral immunodeficiency: Initial (first 30 minutes): 0.8 mg/kg/minute (0.5 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase every 30 minutes (if tolerated) up to: 8 mg/kg/minute (5 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:4em;">Gammagard S/D [Canadian product]: 5% solution: Initial: 0.5 <b>mL</b>/kg/<b>hour</b>; may increase (if tolerated) to a maximum rate of 4 <b>mL</b>/kg/<b>hour</b>. If 5% solution is tolerated at maximum rate, may administer 10% solution with an initial rate of 0.5 <b>mL</b>/kg/<b>hour</b>; may increase (if tolerated) to a maximum rate of 8 <b>mL/</b>kg/<b>hour.</b></p>
<p style="text-indent:-2em;margin-left:4em;">Gammaked 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Chronic inflammatory demyelinating polyneuropathy (CIDP): Initial (first 30 minutes): 2 mg/kg/minute (1.2 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase gradually (if tolerated) to a maximum of 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:6em;">Primary humoral immunodeficiency or immune thrombocytopenia (ITP): Initial (first 30 minutes): 1 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase gradually (if tolerated) to a maximum of 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:4em;">Gammaplex 5%: Primary humoral immunodeficiency or ITP: Initial (first 15 minutes): 0.5 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase every 15 minutes (if tolerated) up to 4 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:4em;">Gammaplex 10%: Primary humoral immunodeficiency or ITP: Initial (first 15 minutes): 0.5 mg/kg/minute (0.3 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase every 15 minutes (if tolerated) up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:4em;">Gamunex-C 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">CIDP: Initial (first 30 minutes): 2 mg/kg/minute (1.2 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase gradually (if tolerated) to a maximum of 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:6em;">Primary humoral immunodeficiency or ITP: Initial (first 30 minutes): 1 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase gradually (if tolerated) to a maximum of 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:4em;">Octagam 5%: Primary humoral immunodeficiency: Initial (first 30 minutes): 0.5 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>); Maintenance: Double infusion rate (if tolerated) every 30 minutes up to a maximum rate of &lt;3.33 mg/kg/minute (4.2 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:4em;">Octagam 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatomyositis: Initial (first 30 minutes): 1 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>); Maintenance: Double infusion rate (if tolerated) every 30 minutes up to a maximum rate of 4 mg/kg/minute (2.4 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:6em;">ITP: Initial (first 30 minutes):1 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>); Maintenance: Double infusion rate (if tolerated) every 30 minutes up to a maximum rate of 12 mg/kg/minute (7.2 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:4em;">Panzyga:</p>
<p style="text-indent:-2em;margin-left:6em;">CIDP: Initial (first 30 minutes): 1 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase gradually (if tolerated) every 15 to 30 minutes up to 12 mg/kg/minute (7.2 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:6em;">ITP: Initial (first 30 minutes): 1 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>); Maintenance: May increase gradually (if tolerated) every 15 to 30 minutes up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:6em;">Primary humoral immunodeficiency: Initial (first 30 minutes): 1 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>); Maintenance: May increase gradually (if tolerated) every 15 to 30 minutes up to 14 mg/kg/minute (8.4 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:4em;">Privigen 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">ITP: Initial: 0.5 mg/kg/minute (0.3 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase gradually (if tolerated) up to 4 mg/kg/minute (2.4 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:-2em;margin-left:6em;">CIDP/Primary humoral immunodeficiency: Initial: 0.5 mg/kg/minute (0.3 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase gradually (if tolerated) up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>SUBQ infusion:</b> Initial dose should be administered in a health care setting capable of providing monitoring and treatment in the event of hypersensitivity. Using aseptic technique, follow the infusion device manufacturer's instructions for filling the reservoir and preparing the pump. Remove air from administration set and needle by priming. After the administration sites are clean and dry, insert subcutaneous needle and prime administration set. Attach sterile needle to administration set, gently pull back on the syringe to assure a blood vessel has not been inadvertently accessed (do not use needle and tubing if blood present). Repeat for each injection site; deliver the dose following instructions for the infusion device. Rotate the site(s) between successive infusions. Treatment may be transitioned to the home/home care setting in the absence of adverse reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">Cutaquig:</p>
<p style="text-indent:-2em;margin-left:6em;">Injection sites: Abdomen, thigh, upper arm, and/or upper leg/hip; ≤6 simultaneous injection sites (spaced ≥2 inches apart).</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum infusion rate: 20 mL/hour per injection site (first 2 infusions); may be increased to 52 mL/hour per injection site (as tolerated) for subsequent infusions.</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum infusion volume: 25 mL per injection site (first 2 infusions); may increase to 40 mL per site for subsequent infusions.</p>
<p style="text-indent:-2em;margin-left:4em;">Cuvitru: <b>Note:</b> Manufacturer recommends to complete administration within 2 hours due to the potential formation of particles caused by siliconized syringes.</p>
<p style="text-indent:-2em;margin-left:6em;">Injection sites: Abdomen, thigh, upper arm, lateral hip (avoid bony prominences); ≤4 simultaneous injection sites (spaced ≥4 inches apart).</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum infusion rate: 10 to 20 mL/hour per injection site (first 2 infusions); may be increased to 60 mL/hour per injection site (as tolerated) for subsequent infusions.</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum infusion volume:</p>
<p style="text-indent:-2em;margin-left:8em;">Patients &lt;40 kg: 20 mL per injection site (first 2 infusions); may increase to 60 mL per site for subsequent infusions.</p>
<p style="text-indent:-2em;margin-left:8em;">Patients ≥40 kg: 60 mL per injection site.</p>
<p style="text-indent:-2em;margin-left:4em;">Gammagard Liquid:</p>
<p style="text-indent:-2em;margin-left:6em;">Injection sites: Abdomen, thigh, upper arm, lower back (avoid bony prominences); ≤8 simultaneous injection sites (spaced ≥2 inches apart).</p>
<p style="text-indent:-2em;margin-left:6em;">Initial infusion rate:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;40 kg: 15 mL/hour per injection site (maximum volume: 20 mL per injection site).</p>
<p style="text-indent:-2em;margin-left:8em;">≥40 kg: 20 mL/hour per injection site (maximum volume: 30 mL per injection site).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance infusion rate:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;40 kg: 15 to 20 mL/hour per injection site (maximum volume: 20 mL per injection site).</p>
<p style="text-indent:-2em;margin-left:8em;">≥40 kg: 20 to 30 mL/hour per injection site (maximum volume: 30 mL per injection site).</p>
<p style="text-indent:-2em;margin-left:4em;">Gammaked, Gamunex-C:</p>
<p style="text-indent:-2em;margin-left:6em;">Injection sites: Abdomen, thigh, upper arm, lateral hip; ≤8 simultaneous injection sites (spaced ≥2 inches apart).</p>
<p style="text-indent:-2em;margin-left:6em;">Recommended infusion rate: 20 mL/hour per infusion site.</p>
<p style="text-indent:-2em;margin-left:4em;">Hizentra:</p>
<p style="text-indent:-2em;margin-left:6em;">Injection sites: Abdomen, thigh, upper arm, lateral hip (avoid scars, stretch marks, and areas that are tender, bruised, red, or hard); ≤8 simultaneous or ≤12 consecutive injection sites in parallel (spaced ≥2 inches apart). Cover infusion sites(s) with a protective dressing after administration.</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum infusion rate: First infusion: 15 mL/hour per injection site (primary humoral immunodeficiency) or 20 mL/hour per injection site (CIDP); subsequent infusions: 25 mL/hour per injection site (primary humoral immunodeficiency) or 50 mL/hour per injection site (CIDP).</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum infusion volume: First infusion: 15 mL per injection site (primary humoral immunodeficiency) or 20 mL per injection site (CIDP); subsequent infusions: 25 mL per injection site (primary humoral immunodeficiency) or 50 mL per injection site (CIDP).</p>
<p style="text-indent:-2em;margin-left:4em;">HyQvia: Infuse the two components of HyQvia (immune globulin and hyaluronidase) sequentially, beginning with hyaluronidase; do not use either component alone. Infusion pump capable of infusing rates up to 300 mL/hour/site is required; must also have the ability to titrate the flow rate. Use a 24 gauge subcutaneous needle set labeled for high flow rates. Infusion site leakage can occur; consider using longer needles (14 mm or 12 mm) and/or more than one infusion site. Initiate the infusion of the full dose of the immune globulin through the same subcutaneous needle set within ~10 minutes of hyaluronidase infusion. For each full or partial vial of immune globulin used, administer the entire contents of the hyaluronidase vial. A second site can be used based on tolerability and total volume; if a second site is used, administer half of total volume of the hyaluronidase in each site. Flush the infusion line with NS or D5W if required.</p>
<p style="text-indent:-2em;margin-left:6em;">Injection sites: Middle to upper abdomen or thigh (avoid bony prominences, or areas that are scarred, inflamed, or infected). If two sites are used simultaneously, the two infusion sites should be on opposite sides of the body.</p>
<p style="text-indent:-2em;margin-left:8em;">Volume per site:</p>
<p style="text-indent:-2em;margin-left:10em;">&lt;40 kg: ≤300 mL per injection site.</p>
<p style="text-indent:-2em;margin-left:10em;">≥40 kg: ≤600 mL per injection site.</p>
<p style="text-indent:-2em;margin-left:6em;">Infusion rate:</p>
<p style="text-indent:-2em;margin-left:8em;">Hyaluronidase: ~1 to 2 mL/minute, or as tolerated.</p>
<p style="text-indent:-2em;margin-left:8em;">Immune globulin:</p>
<p style="text-indent:-2em;margin-left:10em;">First 2 infusions:</p>
<p style="text-indent:-2em;margin-left:12em;">&lt;40 kg: 5 mL/hour for 5 to 15 minutes; 10 mL/hour for 5 to 15 minutes; 20 mL/hour for 5 to 15 minutes; 40 mL/hour for 5 to 15 minutes; then 80 mL/hour for remainder of infusion.</p>
<p style="text-indent:-2em;margin-left:12em;">≥40 kg: 10 mL/hour for 5 to 15 minutes; 30 mL/hour for 5 to 15 minutes; 60 mL/hour for 5 to 15 minutes; 120 mL/hour for 5 to 15 minutes; then 240 mL/hour for remainder of infusion.</p>
<p style="text-indent:-2em;margin-left:10em;">Next 2 or 3 infusions:</p>
<p style="text-indent:-2em;margin-left:12em;">&lt;40 kg: 10 mL/hour for 5 to 15 minutes; 20 mL/hour for 5 to 15 minutes; 40 mL/hour for 5 to 15 minutes; 80 mL/hour for 5 to 15 minutes; then 160 mL/hour for remainder of infusion.</p>
<p style="text-indent:-2em;margin-left:12em;">≥40 kg: 10 mL/hour for 5 to 15 minutes; 30 mL/hour for 5 to 15 minutes; 120 mL/hour for 5 to 15 minutes; 240 mL/hour for 5 to 15 minutes; then 300 mL/hour for remainder of infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">Xembify: <b>Note:</b> Manufacturer recommends to complete administration within 2 hours due to the potential formation of particles caused by siliconized syringes.</p>
<p style="text-indent:-2em;margin-left:6em;">Injection sites: Abdomen, thigh, upper arm, sides, back, lateral hip (avoid bony prominences or areas that are scarred, inflamed, or infected); ≤6 simultaneous injection sites (spaced ≥2 inches apart).</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum infusion rate: 25 mL/hour per injection site.</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum infusion volume: 25 mL per injection site.</p></div>
<div class="block sts drugH1Div" id="F11513261"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Stability is dependent upon the manufacturer and brand. Do not freeze (do not use if previously frozen). Do not shake. Do not heat (do not use if previously heated).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Asceniv: Store under refrigeration at 2°C to 8°C (36°F to 46°F) for up to 36 months from the date of manufacture; may store at ≤25°C (≤77°F) for up to 4 weeks during the first 24 months from the date of manufacture. After 24 months from date of manufacture, may store at ≤25°C (≤77°F) for up to 2 weeks; after storage at room temperature product must be used or discarded.</p>
<p style="text-indent:-2em;margin-left:2em;">Bivigam: Store under refrigeration at 2°C to 8°C (36°F to 46°F) for up to 36 months from the date of manufacture; may store at ≤25°C (≤77°F) for up to 4 weeks during the first 24 months from the date of manufacture. After 24 months from date of manufacture, may store at ≤25°C (≤77°F) for up to 2 weeks; after storage at room temperature product must be used or discarded.</p>
<p style="text-indent:-2em;margin-left:2em;">Carimune NF: Prior to reconstitution, store at or below 30°C (86°F). Following reconstitution in a sterile laminar air flow environment, store under refrigeration.</p>
<p style="text-indent:-2em;margin-left:2em;">Cutaquig: Store at 2°C to 8°C (36°F to 46°F) for up to 36 months from the date of manufacture or at room temperature (≤25°C [≤77°F]) for up to 9 months; do not return vial to refrigerator after it has been stored at room temperature. Keep in original carton to protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Cuvitru: Store at 2°C to 8°C (36°F to 46°F) for up to 36 months or at room temperature (≤25°C [≤77°F]) for up to 24 months; do not return vial to refrigerator after it has been stored at room temperature. Keep in original carton to protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Flebogamma DIF: Store at 2°C to 25°C (36°F to 77°F). Keep in original carton to protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">GamaSTAN: Store at 2°C to 8°C (36°F to 46°F).</p>
<p style="text-indent:-2em;margin-left:2em;">GamaSTAN S/D [Canadian product]: Store under refrigeration at 2°C to 8°C (36°F to 46°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Gammagard Liquid: Prior to use, may store at 2°C to 8°C (36°F to 46°F) for up to 36 months or at ≤ 25°C (≤77°F) for up to 24 months.</p>
<p style="text-indent:-2em;margin-left:2em;">Gammagard S/D: Store at ≤25°C (≤77°F) for up to 24 months. May store diluted solution under refrigeration at 2°C to 8°C (36°F to 46°F) for up to 24 hours if originally prepared in a sterile laminar air flow environment.</p>
<p style="text-indent:-2em;margin-left:2em;">Gammaked: Store at 2°C to 8°C (36°F to 46°F); may be stored at ≤25°C (≤77°F) for up to 6 months.</p>
<p style="text-indent:-2em;margin-left:2em;">Gammaplex: Store at 2°C to 25°C (36°F to 77°F) for up to 36 months from the date of manufacture. Keep in original carton to protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Gamunex-C: Store at 2°C to 8°C (36°F to 46°F) for up to 36 months from the date of manufacture; within this time, may store for up to 6 months at ≤25°C (≤77°F); after storage at ≤25°C (≤77°F) the product must be used or discarded. Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Hizentra: Store at ≤25°C (≤77°F) for up to 30 months from the date of manufacture. Keep in original carton to protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">HyQvia: Store at 2°C to 8°C (36°F to 46°F) for up to 36 months; may store at ≤25°C (≤77°F) for up to 3 months during the first 24 months from the date of manufacture (after 3 months at room temperature, discard); do not return vial to refrigerator after it has been stored at room temperature.</p>
<p style="text-indent:-2em;margin-left:2em;">Octagam 5%: Store at 2°C to 8°C (36°F to 46°F) for 36 months from the date of manufacture; within the first 24 months, may store at ≤25°C (≤77°F); after storage at ≤25°C (≤77°F), the product must be used or discarded.</p>
<p style="text-indent:-2em;margin-left:2em;">Octagam 10%: Store at 2°C to 8°C (36°F to 46°F) for 24 months from the date of manufacture; within these first 12 months, may store up to 9 months at ≤25°C (77°F); after storage at ≤25°C (77°F), the product must be used or discarded.</p>
<p style="text-indent:-2em;margin-left:2em;">Panzyga: Store at 2°C to 8°C (36°F to 46°F) for up to 36 months from the date of manufacture; within this time, may store up to 12 months at ≤25°C (≤77°F); after storage at ≤25°C (≤77°F) the product must be used or discarded. Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Privigen: Store at ≤25°C (≤77°F). Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Xembify: Store at 2°C to 8°C (36°F to 46°F); may be stored at ≤25°C (≤77°F) for up to 6 months; after storage at ≤25°C (≤77°F) the product must be used or discarded. Administer within 8 hours after beginning infusion preparation (ie, once transferred from the vial into a syringe).</p></div>
<div class="block usep drugH1Div" id="F53570152"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of primary humoral immunodeficiency syndromes (may include but not limited to: Congenital agammaglobulinemia, severe combined immunodeficiency syndromes [SCIDS], common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome); acute and chronic immune thrombocytopenia (ITP); chronic inflammatory demyelinating polyneuropathy (CIDP); and multifocal motor neuropathy. Prevention of coronary artery aneurysms associated with Kawasaki syndrome (in combination with aspirin).</p>
<p style="text-indent:0em;margin-top:2em;">Adjunctive treatment of bacterial infection in patients with hypogammaglobulinemia and/or recurrent bacterial infections with B-cell chronic lymphocytic leukemia (CLL); and serious infection in immunoglobulin deficiency (select agammaglobulinemias).</p>
<p style="text-indent:0em;margin-top:2em;">To provide passive immunity for prophylaxis in the following susceptible individuals: Hepatitis A (preexposure and postexposure [within 14 days and prior to manifestation of disease]); measles (postexposure [within 6 days] in an unvaccinated or nonimmune person); rubella (postexposure during early pregnancy); and varicella zoster (immunosuppressed patients when varicella zoster immune globulin is unavailable).</p>
<p style="text-indent:0em;margin-top:2em;">See table for product specific indications, FDA approved age ranges, and routes of administration.</p>
<table border="1" frame="border" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Product</p></th>
<th align="center">
<p style="text-indent:0em;">Indication</p></th>
<th align="center">
<p style="text-indent:0em;">FDA Approval Ages</p></th>
<th align="center">
<p style="text-indent:0em;">Route(s)</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">Asceniv</p></td>
<td align="center">
<p style="text-indent:0em;">Primary immunodeficiency (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">≥12 years and adults</p></td>
<td align="center">
<p style="text-indent:0em;">Intravenous</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Bivigam</p></td>
<td align="center">
<p style="text-indent:0em;">Primary immunodeficiency (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">≥6 years and adults</p></td>
<td align="center">
<p style="text-indent:0em;">Intravenous</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Carimune NF</p></td>
<td align="center">
<p style="text-indent:0em;">Primary immunodeficiency (treatment)</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Pediatric patients (age not specified) and adults</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Intravenous</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Acute and chronic ITP (treatment)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Cutaquig</p></td>
<td align="center">
<p style="text-indent:0em;">Primary immunodeficiency (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">≥2 years and adults</p></td>
<td align="center">
<p style="text-indent:0em;">Subcutaneous</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Cuvitru</p></td>
<td align="center">
<p style="text-indent:0em;">Primary immunodeficiency (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">≥2 years and adults</p></td>
<td align="center">
<p style="text-indent:0em;">Subcutaneous</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Flebogamma 5% DIF</p></td>
<td align="center">
<p style="text-indent:0em;">Primary immunodeficiency (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">≥2 years and adults</p></td>
<td align="center">
<p style="text-indent:0em;">Intravenous</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Flebogamma 10% DIF</p></td>
<td align="center">
<p style="text-indent:0em;">Primary immunodeficiency (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">Adults</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Intravenous</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Chronic ITP (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">≥2 years and adults</p></td></tr>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;">GamaSTAN</p></td>
<td align="center">
<p style="text-indent:0em;">Passive immunity - Hepatitis A</p></td>
<td align="center">
<p style="text-indent:0em;">Adults</p></td>
<td align="center" rowspan="4">
<p style="text-indent:0em;">Intramuscular</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Passive immunity - Measles</p></td>
<td align="center">
<p style="text-indent:0em;">Pediatric patients (age not specified) and adults</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Passive immunity - Rubella</p></td>
<td align="center">
<p style="text-indent:0em;">Adults</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Passive immunity - Varicella</p></td>
<td align="center">
<p style="text-indent:0em;">Adults</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Gammagard Liquid</p></td>
<td align="center">
<p style="text-indent:0em;">Primary immunodeficiency (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">≥2 years and adults</p></td>
<td align="center">
<p style="text-indent:0em;">Intravenous, Subcutaneous</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Multifocal motor neuropathy (MMN)</p></td>
<td align="center">
<p style="text-indent:0em;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;">Intravenous</p></td></tr>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;">Gammagard S/D</p></td>
<td align="center">
<p style="text-indent:0em;">Primary immunodeficiency (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">≥2 years and adults</p></td>
<td align="center" rowspan="4">
<p style="text-indent:0em;">Intravenous</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">B-cell chronic lymphocytic leukemia (CLL)</p></td>
<td align="center">
<p style="text-indent:0em;">Adults</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Chronic ITP (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">Adults</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Kawasaki syndrome</p></td>
<td align="center">
<p style="text-indent:0em;">Pediatric patients (age not specified)</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Gammaked</p></td>
<td align="center">
<p style="text-indent:0em;">Primary immunodeficiency (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">≥2 years and adults</p></td>
<td align="center">
<p style="text-indent:0em;">Intravenous, Subcutaneous</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Acute and chronic ITP (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">Pediatric patients (age not specified) and adults</p></td>
<td align="center">
<p style="text-indent:0em;">Intravenous</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Chronic inflammatory demyelinating polyneuropathy (CIDP)</p></td>
<td align="center">
<p style="text-indent:0em;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;">Intravenous</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Gammaplex 5%</p></td>
<td align="center">
<p style="text-indent:0em;">Primary immunodeficiency (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">≥2 years and adults</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Intravenous</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Chronic ITP (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">Adults</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Gammaplex 10%</p></td>
<td align="center">
<p style="text-indent:0em;">Primary immunodeficiency (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">≥2 years and adults</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Intravenous</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Chronic ITP (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">Adults</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Gamunex-C</p></td>
<td align="center">
<p style="text-indent:0em;">Primary immunodeficiency (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">≥2 years and adults</p></td>
<td align="center">
<p style="text-indent:0em;">Intravenous, Subcutaneous</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Acute and chronic ITP (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">Pediatric patients (age not specified) and adults</p></td>
<td align="center">
<p style="text-indent:0em;">Intravenous</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Chronic inflammatory demyelinating polyneuropathy (CIDP)</p></td>
<td align="center">
<p style="text-indent:0em;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;">Intravenous</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Hizentra</p></td>
<td align="center">
<p style="text-indent:0em;">Primary immunodeficiency (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">≥2 years and adults</p></td>
<td align="center">
<p style="text-indent:0em;">Subcutaneous</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Chronic inflammatory demyelinating polyneuropathy (CIDP)</p></td>
<td align="center">
<p style="text-indent:0em;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;">Subcutaneous</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">HyQvia</p></td>
<td align="center">
<p style="text-indent:0em;">Primary immunodeficiency (treatment), in conjunction with recombinant human hyaluronidase</p></td>
<td align="center">
<p style="text-indent:0em;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;">Subcutaneous</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Octagam 5%</p></td>
<td align="center">
<p style="text-indent:0em;">Primary immunodeficiency (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">6 to 16 years and adults</p></td>
<td align="center">
<p style="text-indent:0em;">Intravenous</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Octagam 10%</p></td>
<td align="center">
<p style="text-indent:0em;">Chronic ITP (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;">Intravenous</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Panzyga</p></td>
<td align="center">
<p style="text-indent:0em;">Primary immunodeficiency (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">≥2 years and adults</p></td>
<td align="center">
<p style="text-indent:0em;">Intravenous</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Chronic ITP (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;">Intravenous</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Privigen</p></td>
<td align="center">
<p style="text-indent:0em;">Primary immunodeficiency (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">≥3 years and adults</p></td>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Intravenous</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Chronic ITP (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">≥15 years and adults</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Chronic inflammatory demyelinating polyneuropathy (CIDP)</p></td>
<td align="center">
<p style="text-indent:0em;">Adults</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Xembify</p></td>
<td align="center">
<p style="text-indent:0em;">Primary immunodeficiency (treatment)</p></td>
<td align="center">
<p style="text-indent:0em;">≥2 years and adults</p></td>
<td align="center">
<p style="text-indent:0em;">Subcutaneous</p></td></tr></tbody></table>
<p style="text-indent:0em;margin-top:2em;">Has also been used for acute disseminated encephalomyelitis (ADEM), acute myocarditis, chronic <i>Clostridioides</i>
<i>difficile</i> colitis, Guillain-Barré syndrome, hematopoietic stem cell transplantation with hypogammaglobulinemia, isoimmune hemolytic disease (Rh-incompatibility), multiple sclerosis, multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2, myasthenia gravis, neonatal sepsis, pediatric HIV infection and associated thrombocytopenia, refractory dermatomyositis, Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), and refractory polymyositis.</p></div>
<div class="block mst drugH1Div" id="F11513231"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gamimune N may be confused with CytoGam</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Immune globulin (intravenous) may be confused with hepatitis B immune globulin</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Privigen (immune globulin) may be confused with Albuminar-25 (albumin) due to similar packaging </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299513"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F11513254"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May enhance the thrombogenic effect of Immune Globulin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pozelimab: Immune Globulin may diminish the therapeutic effect of Pozelimab.  Management: Avoid concurrent use of intravenous immunoglobulin with pozelimab. If the combination cannot be avoided, monitor for evidence of a diminished effect of pozelimab and worsening underlying disease.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ravulizumab: Immune Globulin may decrease the serum concentration of Ravulizumab.  Management: Administer a supplemental dose of ravulizumab (600 mg) within 4 hours of completion of the immune globulin cycle.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Live organism vaccination should be withheld for as long as 6 to 11 months following immune globulin administration. Recommendations vary by product and immune globulin dose, see full monograph for details.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block dic drugH1Div" id="F11513281"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium.</p></div>
<div class="block pri drugH1Div" id="F11513244"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009). In a study of 2 women treated with IV immune globulin (IVIG) for common variable immunodeficiency, exogenous immune globulin was shown to cross the placenta similar to endogenous immune globulin (Palmeira 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Limited outcome data are available from 8 pregnancies with known outcomes reported to the HyQvia pregnancy registry.</p>
<p style="text-indent:0em;margin-top:2em;">IVIG has been recommended for use in fetal-neonatal alloimmune thrombocytopenia and pregnancy-associated immune thrombocytopenia (ITP) (ACOG 207 2019; ASH [Neunert 2011]; Pacheco 2011; Winkelhorst 2017); use is appropriate for ITP in cases refractory to corticosteroids, when side effects to corticosteroids are significant, or when a rapid increase in platelets is needed (ACOG 207 2019). IVIG is recommended to prevent measles in nonimmune patients exposed during pregnancy (CDC 2013). IVIG may be used when a prompt response for the treatment of myasthenia gravis is needed during pregnancy (Sanders 2016).</p></div>
<div class="block mopp drugH1Div" id="F53570150"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function (prior to initial infusion and at appropriate intervals), urine output, IgG concentrations, hemoglobin and hematocrit, platelets (in patients with ITP); infusion- or injection-related adverse reactions, anaphylaxis, signs and symptoms of hemolysis; blood viscosity (in patients at risk for hyperviscosity); presence of antineutrophil antibodies (if TRALI is suspected); volume status; neurologic symptoms (if aseptic meningitis syndrome suspected); pulmonary adverse reactions; clinical response (as defined by disease state); monitor for fluid overload in patients with cardiac dysfunction being treated for multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 (ACR [Henderson 2022]; NIH 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">For patients at high risk of hemolysis (dose ≥2,000 mg/kg, given as a single dose or divided over several days, and non-O blood type): Hemoglobin or hematocrit prior to and 36 to 96 hours postinfusion.</p>
<p style="text-indent:-2em;margin-left:2em;">SubQ infusion: Primary immunodeficiency: Monitor IgG trough levels every 2 to 3 months before/after conversion from IV; subcutaneous infusions provide more constant IgG levels than usual IV immune globulin treatments.</p></div>
<div class="block pha drugH1Div" id="F11513265"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Replacement therapy for primary and secondary immunodeficiencies, and IgG antibodies against bacteria, viral, parasitic and mycoplasma antigens; interference with F<sub>c</sub> receptors on the cells of the reticuloendothelial system for autoimmune cytopenias and ITP; provides passive immunity by increasing the antibody titer and antigen-antibody reaction potential </p></div>
<div class="block phk drugH1Div" id="F11513267"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: IV: Provides immediate antibody levels.</p>
<p style="text-indent:-2em;margin-left:4em;">Immune thrombocytopenia: Initial response: 1 to 3 days; Peak response: 2 to 7 days (ASH [Neunert 2011]).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: IM, IV: Immune effect: 3 to 4 weeks (variable).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 0.05 to 0.13 L/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Intravascular portion (primarily): Healthy subjects: 41% to 57%; Patients with congenital humoral immunodeficiencies: ~70%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IM: ~23 days; SUBQ: ~59 days (HyQvia); IV: IgG (variable among patients): Healthy subjects: 14 to 24 days; Patients with congenital humoral immunodeficiencies: 26 to 40 days; hypermetabolism associated with fever and infection have coincided with a shortened half-life.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">Plasma: SUBQ: Cutaquig: ~2 days; Cuvitru: ~4.4 days; Gammagard Liquid: 2.9 days; Hizentra: 2.9 days; HyQvia: ~5 days; Xembify: ~3 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Serum: IM: ~48 hours.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F22059490"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cuvitru | Globuman | Hizentra | Hyqvia | Kiovig | Privigen | Sandoglobulin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Citax F | Endobulin s/d | Endobulin-ht | Flebogamma | Gamimune n | Gammagard s/d | Gammaglo.Seric.Hum | Hyqvia | Ig vena | Kiovig | Octagam | Panzyga | Pentaglobin | Sandoglobulina | Seroglubin t | Vigam</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Beriglobin p | Cutaquig | Cuvitru | Endobulin | Endobulin s/d | Gamma venin p | Gammagard s/d | Gamunex | Hizentra | Hyqvia | Intraglobin f | Octagam | Optiglobin | Panzyga | Pentaglobin | Privigen | Sandoglobulin | Venimmun n</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cuvitru | Evogam | Flebogamma dif | Gammagard | Intragam p | Intraglobin f | Privigen | Sandoglobulin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Normoglobin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cutaquig | Gammabuline | Gammagard | Gamunex | Iqymune | Kiovig | Multigam | Nanogam | Octagam | Panzyga | Sandoglobuline</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cutaquig | Immunovenin | Immunovenin-Intact | Kiovig | Octagam | Pentaglobin | Privigen</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Armoglobulina p | Beriglobina | Blauimuno | Cuvitru | Endobulin | Flebogamma | Gamaglobulina im grifols | Gamma venina | Hizentra | Hyqvia | Ig vena | Imunoglobulin | Intratect | Octagam | Pentaglobin | Tegeline</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cutaquig | Cuvitru | Hizentra | Hyqvia | Ig vena | Intratect | Iqymune | Kiovig | Privigen | Redimune | Redimune nf</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Gamma</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Flebogamma | Gamimune n | Hizentra</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Gammaraas | Human immunoglobulin(pH4) | Rong sheng jing bing | Rongsheng imig | Rongsheng ivig</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Blauimuno | Clairyg | Cuvitru | Flebogamma | Flebogamma dif | Gammaraas | Gamunex c | Globuman | Hizentra | Hyqvia | Ig vena | Inmunoglobulina | Intratect | Kiovig | Octagam | Panzyga | Pentaglobin | Privigen | Sandoglobulina | Vigam</span>;</li>
<li>
<span class="countryCode">(CY)</span> <span class="country">Cyprus</span><span class="countrySeparator">: </span><span class="drugName">Flebogamma</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cuvitru | Endobulin | Flebogamma | Gamma venin | Gamma venin p | Gamunex | Human immunoglobulin | Hyqvia | Igamplia | Kiovig | Octagam | Panzyga | Pentaglobin | Veinoglobuline | Venimmun</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Beriglobin | Cutaquig | Cuvitru | Flebogamma | Flebogamma dif | Flebogammadif | Gamma venin | Gammagard | Gammonativ | Gamunex | Hizentra | Hyqvia | Ig vena | Immunglobulin | Intratect | Intrimun | Iqymune | Kiovig | Octagam | Optiglobin | Pentaglobin | Polyglobin a | Privigen | Sandoglobulin | Subcuvia | Venimmun | Yimmugo</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Immunglobulin zlb behring</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Globuman | Octagam | Sandoglobulina</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Beriglobina | Flebogamma dif | Globuman | Hizentra | Kiovig | Privigen | Sandoglobulina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Endobulin | Gammagard sd | Hyqvia | Kiovig | Octagam | Panzyga | Pentaglobin | Privigen | Sandoglobulin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Globulin | Globuman</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Alergogamma | Beriglobina | Beriglobina p | Endobulin s/d | Flebogamma | Gammagard s/d | Gamunex | Hizentra | Hyqvia | Intratect | Iqymune | Kiovig | Octagamocta | Panzyga | Poliglobin n | Privigen | Vivaglobin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Beriglobin | Cutaquig | Endobulin | Flebogamma dif | Gamma venin | Gammagard | Gammanorm | Gamunex | Hyqvia | Intratect | Intratect 100 g/l | Kiovig | Octagam | Privigen | Venogamma</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Clairyg | Cutaquig | Cuvitru | Endobuline | Flebogamma dif | Gammagard | Gamunex | Hizentra | Humaglobin | Hyqvia | Intratect | Octagam | Panzyga | Sandoglobuline | Tegeline</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Alphaglobin | Cutaquig | Cuvitru | Endobulin | Flebogammadif | Gamimune | Gamimune n | Gammagard | Gammaplex | Gammonativ | Hizentra | Human norm igg | Hyqvia | Iqymune | Kabiglobulin | Kiovig | Normal immunoglobulin | Octagam | Panzyga | Sandoglobulin | Subcuvia | Venoglobulin | Vigam | Vigam s</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Flebogamma | Gaminex | Gammagard sd | Hizentra | Hyqvia | Ig vena | Intraglobin f | Kiovig | Octagam | Pentaglobin | Privigen | Sandoglobulin | Vigam</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Cuvitru | Flebogamma | Gamastan | Gammagard | Hizentra | Intratect | Privigen</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Gammagard s/d | Hyqvia | Ig vena | Intratect | Kiovig | Octagam | Privigen</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Endobulin | Gammanorm | Gamunex | Humaglobin ig. | Hyqvia | Ig vena | Intraglobin cp | Intraglobin f | Intratect | Kiovig | Panzyga | Sandoglobulin | Vivaglobin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Gamimune n s/d | Gamma 16 | Gamma venin p | Gamunex | Intratect | Privigen | Venoglobulin s</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Alphaglobin | Cutaquig | Cuvitru | Flebogamma | Gammagard s/d | Hizentra | Hyqvia | Intraglobin f | Intratect | Kiovig | Privigen</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Sandoglobulin | Vigam</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bharglob | Emglobulin | Gamma | Genexglob | Globucel | Globugold | Globuwok | Humanig | Igwok | Immuglo | Iviglob-ex | Pentaglobin | Zyglobe</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Biaven | Cutaquig | Cuvitru | Endobulin | Flebogamma | Flebogamma dif | Gammagard s/d | Globiga | Haimaven vi | Hyqvia | Ig gamma | Ig vena | Intraglobin f | Intratect | Iqymune | Keycute | Naxiglo | Normogamma | Pentaglobin | Plitagamma | Privigen | Sandoglobulina | Uman gamma | Venimmun | Venogamma | Vivaglobin</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Globuman | Intraglobin f</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Beriglobin | Gamastan | Gamma venin | Gammagard | Globulin | Globulin hyland | Globulin n | Globulin v | Glovenin i | Ivgg | Polyglobin | Polyglobin n | Privigen | Sanglopor | Venilon fujisawa | Venilon teijin | Venoglobulin | Venoglobulin i | Venoglobulin ih</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Gamma | Humaglobin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">I.V.-Globulin | Liv gamma | Liv gamma sn | Veno gamma</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Beriglobin p | Gamunex c | Hyqvia | Ig vena | Kiovig | Pentaglobin | Privigen</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Clairyg | Globuman | Octagam | Pentaglobin | Privigen | Sandoglobulin | Venimmun n</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cutaquig | Endobulin s/d | Gamma venin | Gammagard sd | Immunovenin | Intraglobin f | Ivega | Kiovig | Octagam | Panzyga | Pentaglobin | Venimmun</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Globuman | Sandoglobulin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cutaquig | Endobulin | Gamma venin | Gammagard s/d | Hyqvia | Immunoglobulinum humanum | Immunovenin | Ivega | Kiovig | Panzyga | Pentaglobin | Venimmun</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Beriglobina | Beriglobina p | Cuvitru | Endobulin | Endobulin s/d | Flebogamma | Gammaglobulina humana pasteurizada grifols | Gamunex c | Higlobin | Hizentra | Intratect | Kedrigamma | Kiovig | Liv gamma sn | Octagam | Pentaglobin | Sandoglobul | Sandoglobulina | Seroglubin | Tegeline | Vigam</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Flebogamma | Gamma veinine | Gamunex c | Globuman Berna | Hizentra | Intrapure | Octagam | Privigen | Vigam</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cutaquig | Cuvitru | Flebogamma | Flebogamma dif | Flebogammadif | Gamma 16 | Gammagard | Gammagard s/d | Gammaquin | Hizentra | Intraglobin f | Intratect | Kiovig | Nanogam | Octagam | Panzyga | Privigen</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Beriglobin | Cuvitru | Hizentra | Hyqvia | Intratect 100 g/l | Kiovig | Octagam | Panzyga | Pentaglobin | Privigen | Vivaglobin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Globuman | Hizentra | I.V. globulin sn | Octagam</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Bioven mono | Endobulin s/d | Gamimune | Gamimune-n s/d | Gammagard | Globuman | Humoglob | I.V. globulin sn | Ig vena | Iv-globulin | Octagam | Privigen | Proivig</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Gamimune n | Globuman | Intratect | Pentaglobin | Privigen | Sandoglobulin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Beriglobin | Endobulin | Flebogamma | Gamma venin | Gamma venin p | Gammagard s/d | Gammagard sd | Ig vena | Intraglobin f | Nanogy | Octagam | Pentaglobin | Sandoglobulin | Sandoglobulin p | Veinoglobuline | Venimmun | Vivaglobin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Baygam | Carimune | Cutaquig | Cuvitru | Flebogamma dif | Gamimune n | Gammagard | Gammagard sd | Gammaplex | Gamunex | Gamunex c | Hizentra | Iveegam | Sandoglobulin | Venoglobulin s</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Beriglobin | Cutaquig | Flebogammadif | Gamunex | Hizentra | Intratect | Panzyga | Privigen</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Flebogamma | I v globulin sn green cross | Inmunoglobulina humana | Inmunoglobulina humana imedic | Inmunoglobulina humana kedrion | Inmunoglobulina humana normal octapharma | Inmunoglobulina humana quimfa | Octagam | Panzyga | Privigen</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Cuvitru | Hizentra 20% | Kiovig | Pentaglobin | Privigen</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cutaquig | Endobulin s/d | Flebogamma | Flebogamma dif | Hizentra | Humaglobin | Hyqvia | Ig vena | Intratect | Kiovig | Octagam | Panzyga | Pentaglobin | Privigen</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Biaven v.i. | Cutaquig | Endobulin s/d | Flebogamma | Gabreglobine | Gabriglobin IgG | Gamimune n | Gamunex | Humaglobin | Human normal immunoglobuline | I.g. vena n.i.v. | Imbiogam | Imbioglobulin | Imbioglobuline | Immunoglobulin cheloveka normalnyj | Immunoglobulin complex preparation | Immunoglobulin sigardis | Immunoglobulinum humanum | Intraglobin | Intratect | Kiovig | Normal human immunoglobulin | Octagam | Pentaglobin | Privigen | Sandoglobulin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Gamunex | Hizentra | Hyqvia | Ig vena | Intraglobin | Kiovig | Liv gamma sn | Nanogam | Octagam | Panzyga | Pentaglobin | Vigam</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cutaquig | Cuvitru | Hizentra | Hyqvia | Intratect | Intratect 100 g/l | Kiovig | Octagam | Panzyga | Privigen | Xembify</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Flebogamma | Gamimune n | Gammagard | Hizentra | Intragam p | Octagam | Privigen | Venoglobulin s</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Endobulin | Kiovig | Octagam</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cuvitru | Endobulin | Flebogamma | Gamunex | Hizentra | Hyqvia | Igamplia | Ivega | Kiovig | Octagam | Panzyga | Sandoglobulin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Flebogamma | Gammaraas | Gamunex c | Globuman berna iv | Hizentra | Human immunoglobulin | Immunoglobulin 5 trcs | Intraglobin f | Iv-globulin | Kiovig | Octagam | Pentaglobin | Privigen | Venoglobulin s | Vigam s</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Beriglobin | Intraglobin | Privigen | Tegeline</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Biaven | Cuvitru | Endobulin | Flebogamma | Flebogamma dif | Gamimune n | Gammagard s/d | Gammar p | Genivig | Hizentra | Hyqvia | Immutect | Intratect | Isiven | Kiovig | Nanogam | Nordimmun | Octagam | Pentaglobin | Privigen | Ronsenglob | Sandoglobulin | Shuyang Human Immunoglobulin | Vena n | Vigam</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Beriglobin p | Flebogamma | Gamimune n | Gamma-venin p | Gammar p | Globulin | Hizentra | Human Immunoglbulin | Intraglobin | Intraglobin f | Kiovig | Octagam | Privigen | Veinoglobuline</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Flebogamma | Octagam | Sandoglobulin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Beriglobina | Gamunex | Ig vena | Sandoglobulina | Seroglubin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Flebogamma | RosenGlob</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cutaquig | Cuvitru | Cuvitru 1 | Cuvitru 2 | Cuvitru 4 | Cuvitru 8 | Endobulin | Globuman Berna | Globuman berna i v | Hizentra | Intragam | Intratect | Pentaglobin | Polygam | Privigen</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-20924675">
<a name="20924675"></a>Abougergi MS and Kwon JH, "Intravenous Immunoglobulin for the Treatment of <i>Clostridium difficile</i> Infection: A Review," <i>Dig Dis Sci</i>, 2011, 56(1):19-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/20924675/pubmed" id="20924675" target="_blank">20924675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33532696">
<a name="33532696"></a>Abraham D, Kalyanasundaram S, Krishnamurthy K. Refractory Kawasaki disease-a challenge for the pediatrician. <i>SN Compr Clin Med</i>. 2021;3(3):855-860. doi:10.1007/s42399-021-00775-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/33532696/pubmed" id="33532696" target="_blank">33532696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36198179">
<a name="36198179"></a>Aggarwal R, Charles-Schoeman C, Schessl J, et al; ProDERM Trial Group. Trial of intravenous immune globulin in dermatomyositis. <i>N Engl J Med</i>. 2022;387(14):1264-1278. doi:10.1056/NEJMoa2117912<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/36198179/pubmed" id="36198179" target="_blank">36198179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19293008">
<a name="19293008"></a>Amagai M, Ikeda S, Shimizu H, et al; Pemphigus Study Group. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. <i>J Am Acad Dermatol.</i> 2009;60(4):595-603. doi:10.1016/j.jaad.2008.09.052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/19293008/pubmed" id="19293008" target="_blank">19293008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2">
<a name="AAP.2"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15231951">
<a name="15231951"></a>American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. <i>Pediatrics. </i>2004;114(1):297-316.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/15231951/pubmed" id="15231951" target="_blank">15231951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30801473">
<a name="30801473"></a>American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 207: thrombocytopenia in pregnancy. <i>Obstet Gynecol</i>. 2019;133(3):e181-e193. doi:10.1097/AOG.0000000000003100<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/30801473/pubmed" id="30801473" target="_blank">30801473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17397769">
<a name="17397769"></a>Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. <i>Transfus Med Rev</i>. 2007;21(2)(suppl 1):s9-s56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/17397769/pubmed" id="17397769" target="_blank">17397769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33956488">
<a name="33956488"></a>Anderson PO. Monoclonal antibodies during breastfeeding.<i> Breastfeed Med</i>. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/33956488/pubmed" id="33956488" target="_blank">33956488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Arnold.1">
<a name="Arnold.1"></a>Arnold DM. Immune thrombocytopenia (ITP) in adults: initial treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed October 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADMA.1">
<a name="ADMA.1"></a>Asceniv (immune globulin intravenous [human]) [prescribing information]. Boca Raton, FL: ADMA Biologics; received September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1598949">
<a name="1598949"></a>ASHP Commission on Therapeutics. ASHP Therapeutic Guidelines for Intravenous Immune Globulin. <i>Am J Hosp Pharm.</i> 1992;49(3):652-654.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/1598949/pubmed" id="1598949" target="_blank">1598949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8797464">
<a name="8797464"></a>Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. <i>Neurology.</i> 1996;47(3):678-683.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/8797464/pubmed" id="8797464" target="_blank">8797464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ballow.1">
<a name="Ballow.1"></a>Ballow M, Shehata N. Overview of intravenous immune globulin (IVIG) therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed August 17, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34480762">
<a name="34480762"></a>Baradaran H, Dashti-Khavidaki S, Taher M, Talebian M, Nasiri-Toosi M, Jafarian A. Antibody-mediated rejection in adult liver transplant recipients: a case series and literature review. <i>J Clin Pharmacol</i>. 2022;62(2):254-271. doi:10.1002/jcph.1963<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/34480762/pubmed" id="34480762" target="_blank">34480762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21562253">
<a name="21562253"></a>Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. <i>Neurology</i>. 2011;76(23):2017-2023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/21562253/pubmed" id="21562253" target="_blank">21562253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.1">
<a name="Expert.1"></a>Based on expert opinion.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9535308">
<a name="9535308"></a>Bassan H, Muhlbaur B, Tomer A, et al, "High-Dose Intravenous Immunoglobulin in Transient Neonatal Myasthenia Gravis," <i>Pediatr Neurol</i>, 1998, 18(2):181-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/9535308/pubmed" id="9535308" target="_blank">9535308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Biotest.1">
<a name="Biotest.1"></a>Bivigam (immune globulin intravenous [human]) [prescribing information]. Boca Raton, FL: ADMA Biologics; received September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15945566">
<a name="15945566"></a>Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. <i>Ann Allergy Asthma Immunol</i>. 2005;94(5 Suppl 1):S1-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/15945566/pubmed" id="15945566" target="_blank">15945566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26371839">
<a name="26371839"></a>Bonilla FA, Khan DA, Ballas ZK, et al; Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma &amp; Immunology; the American College of Allergy, Asthma &amp; Immunology; and the Joint Council of Allergy, Asthma &amp; Immunology. Practice parameter for the diagnosis and management of primary immunodeficiency. <i>J Allergy Clin Immunol.</i> 2015;136(5):1186-1205.e1-78. doi:10.1016/j.jaci.2015.04.049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/26371839/pubmed" id="26371839" target="_blank">26371839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34172516">
<a name="34172516"></a>Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. <i>J Immunother Cancer.</i> 2021;9(6):e002435. doi:10.1136/jitc-2021-002435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/34172516/pubmed" id="34172516" target="_blank">34172516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30973852">
<a name="30973852"></a>Brennan J, Moore K, Sizemore L, et al. Notes from the field: acute hepatitis A virus infection among previously vaccinated persons with HIV infection - Tennessee, 2018.<i> MMWR Morb Mortal Wkly Rep.</i> 2019;68(14):328-329. doi:10.15585/mmwr.mm6814a3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/30973852/pubmed" id="30973852" target="_blank">30973852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12588344">
<a name="12588344"></a>British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. <i>Br J Haematol.</i> 2003;120(4):574-596. doi:10.1046/j.1365-2141.2003.04131.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/12588344/pubmed" id="12588344" target="_blank">12588344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31412178">
<a name="31412178"></a>Brodsky RA. Warm autoimmune hemolytic anemia.<i> N Engl J Med.</i> 2019;381(7):647-654. doi:10.1056/NEJMcp1900554<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/31412178/pubmed" id="31412178" target="_blank">31412178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brugnara.1">
<a name="Brugnara.1"></a>Brugnara C, Brodsky RA. Warm autoimmune hemolytic anemia (AIHA) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed May 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Carimune.2016.11">
<a name="Carimune.2016.11"></a>Carimune (immune globulin intravenous [human]) [prescribing information]. Kankakee, IL: CSL Behring AG; November 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CarimuneNF.2018.05">
<a name="CarimuneNF.2018.05"></a>Carimune NF (immune globulin intravenous [human]) [prescribing information]. Kankakee, IL: CSL Behring LLC; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33557873">
<a name="33557873"></a>Cattalini M, Taddio A, Bracaglia C, et al. Childhood multisystem inflammatory syndrome associated with COVID-19 (MIS-C): a diagnostic and treatment guidance from the Rheumatology Study Group of the Italian Society of Pediatrics. <i>Ital J Pediatr</i>. 2021;47(1):24. doi:10.1186/s13052-021-00980-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/33557873/pubmed" id="33557873" target="_blank">33557873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11475328">
<a name="11475328"></a>Centers for Disease Control and Prevention (CDC). Control and prevention of rubella: evaluation and management of suspected outbreaks, rubella in pregnant women, and surveillance for congenital rubella syndrome. <i>MMWR Recomm Rep. </i>2001;50(RR-12):1-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/11475328/pubmed" id="11475328" target="_blank">11475328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). Hepatitis A Questions and Answers for Health Professionals. Updated October 2017. <a href="https://www.cdc.gov/hepatitis/hav/havfaq.htm" target="_blank">https://www.cdc.gov/hepatitis/hav/havfaq.htm</a>. Accessed October 10, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16708058">
<a name="16708058"></a>Centers for Disease Control and Prevention (CDC). Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep.</i> 2006;55(RR-7):1-23. <a href="https://www.cdc.gov/mmwr/PDF/rr/rr5507.pdf" target="_blank">http://www.cdc.gov/mmwr/PDF/rr/rr5507.pdf</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/16708058/pubmed" id="16708058" target="_blank">16708058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23760231">
<a name="23760231"></a>Centers for Disease Control and Prevention (CDC). Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep.</i> 2013;62(RR-04):1-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/23760231/pubmed" id="23760231" target="_blank">23760231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28910270">
<a name="28910270"></a>Centers for Disease Control and Prevention (CDC). Updated dosing instructions for immune globulin (human) GamaSTAN S/D for hepatitis A virus prophylaxis. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(36):959-960.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/28910270/pubmed" id="28910270" target="_blank">28910270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17947967">
<a name="17947967"></a>Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP). Update: prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Morb Mortal Wkly Rep</i>. 2007;56(41):1080-1084.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/17947967/pubmed" id="17947967" target="_blank">17947967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7909099">
<a name="7909099"></a>Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. <i>Lancet</i>. 1994;343(8905):1059-1063.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/7909099/pubmed" id="7909099" target="_blank">7909099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27490417">
<a name="27490417"></a>Cheng EY, Everly MJ, Kaneku H, et al. Prevalence and clinical impact of donor-specific alloantibody among intestinal transplant recipients. <i>Transplantation</i>. 2017;101(4):873-882. doi:10.1097/TP.0000000000001391<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/27490417/pubmed" id="27490417" target="_blank">27490417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26281140">
<a name="26281140"></a>Cheng EY, Kaneku H, Farmer DG. The role of donor-specific antibodies in intestinal transplantation: experience at the University of California Los Angeles and literature review. <i>Clin Transpl</i>. 2014:153-159.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/26281140/pubmed" id="26281140" target="_blank">26281140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11840450">
<a name="11840450"></a>Cherin P, Pelletier S, Teixeira A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. <i>Arthritis Rheum.</i> 2002;46(2):467-474. doi:10.1002/art.10053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/11840450/pubmed" id="11840450" target="_blank">11840450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol.</i> 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25838326">
<a name="25838326"></a>Colvin MM, Cook JL, Chang P, et al; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiopulmonary Critical Care, Perioperative and Resuscitation; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiovascular Disease in the Young; et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;131(18):1608-1639.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/25838326/pubmed" id="25838326" target="_blank">25838326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30776902">
<a name="30776902"></a>Colvin MM, Cook JL, Chang PP, et al; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Cardiovascular Surgery and Anesthesia. Sensitization in heart transplantation: emerging knowledge: a scientific statement from the American Heart Association. <i>Circulation</i>. 2019;139(12):e553-e578. doi:10.1161/CIR.0000000000000598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/30776902/pubmed" id="30776902" target="_blank">30776902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20643330">
<a name="20643330"></a>Costanzo MR, Dipchand A, Starling R, et al; International Society of Heart and Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients. <i>J Heart Lung Transplant</i>. 2010;29(8):914-956. doi:10.1016/j.healun.2010.05.034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/20643330/pubmed" id="20643330" target="_blank">20643330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Octapharma.1">
<a name="Octapharma.1"></a>Cutaquig (immune globulin subcutaneous human) [prescribing information]. Paramus, NJ: Octapharma USA Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pfizer.1">
<a name="Pfizer.1"></a>Cutaquig (immune globulin subcutaneous human) [prescribing information]. New York, NY: Pfizer Labs; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Octapharma.2">
<a name="Octapharma.2"></a>Cutaquig (immune globulin subcutaneous human) [product monograph]. Toronto, Ontario, Canada: Octapharma Canada Inc; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baxalta.1">
<a name="Baxalta.1"></a>Cuvitru (immune globulin subcutaneous [human]) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18423257">
<a name="18423257"></a>Czernik A, Beutner EH, Bystryn JC. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus. <i>J Am Acad Dermatol.</i> 2008;58(5):796-801. doi:10.1016/j.jaad.2008.01.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/18423257/pubmed" id="18423257" target="_blank">18423257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8247075">
<a name="8247075"></a>Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. <i>N Engl J Med.</i> 1993;329(27):1993-2000.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/8247075/pubmed" id="8247075" target="_blank">8247075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20858553">
<a name="20858553"></a>Danieli MG, Pettinari L, Moretti R, Logullo F, Gabrielli A. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. <i>Autoimmun Rev.</i> 2011;10(3):144-149. doi:10.1016/j.autrev.2010.09.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/20858553/pubmed" id="20858553" target="_blank">20858553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24051350">
<a name="24051350"></a>Dantal J. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk. <i>Am J Nephrol</i>. 2013;38(4):275-284. doi:10.1159/000354893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/24051350/pubmed" id="24051350" target="_blank">24051350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17596722">
<a name="17596722"></a>Daphnis E, Stylianou K, Alexandrakis M, et al. Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy. <i>Nephron Clin Pract</i>. 2007;106(4):c143-c148.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/17596722/pubmed" id="17596722" target="_blank">17596722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12884156">
<a name="12884156"></a>Darenberg J, Ihendyane N, Sjölin J, et al; StreptIg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. <i>Clin Infect Dis</i>. 2003;37(3):333-340. doi:10.1086/376630<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/12884156/pubmed" id="12884156" target="_blank">12884156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20455878">
<a name="20455878"></a>de Kort H, Munivenkatappa RB, Berger SP, et al. Pancreas allograft biopsies with positive C4d staining and anti-donor antibodies related to worse outcome for patients. <i>Am J Transplant</i>. 2010;10(7):1660-1667. doi:10.1111/j.1600-6143.2010.03079.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/20455878/pubmed" id="20455878" target="_blank">20455878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26303035">
<a name="26303035"></a>Del Bello A, Congy-Jolivet N, Danjoux M, et al. De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients. <i>Transpl Int</i>. 2015;28(12):1371-1382. doi:10.1111/tri.12654<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/26303035/pubmed" id="26303035" target="_blank">26303035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27273869">
<a name="27273869"></a>Demetris AJ, Bellamy C, Hübscher SG, et al. 2016 comprehensive update of the Banff Working Group on Liver Allograft Pathology: introduction of antibody-mediated rejection. <i>Am J Transplant</i>. 2016;16(10):2816-2835. doi:10.1111/ajt.13909<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/27273869/pubmed" id="27273869" target="_blank">27273869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8281654">
<a name="8281654"></a>Drucker NA, Colan SD, Lewis AB, et al, "Gamma-Globulin Treatment of Acute Myocarditis in the Pediatric Population," <i>Circulation</i>, 1994, 89(1):252-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/8281654/pubmed" id="8281654" target="_blank">8281654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21908504">
<a name="21908504"></a>Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M; ESMO Guidelines Working Group. Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol.</i> 2011;22(suppl 6):vi50-vi54. doi:10.1093/annonc/mdr377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/21908504/pubmed" id="21908504" target="_blank">21908504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30973192">
<a name="30973192"></a>Eid AJ, Ardura MI; AST Infectious Diseases Community of Practice. Human parvovirus B19 in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant.</i> 2019;33(9):e13535. doi:10.1111/ctr.13535<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/30973192/pubmed" id="30973192" target="_blank">30973192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eisen.1">
<a name="Eisen.1"></a>Eisen HJ, Khush KK. Heart transplantation in adults: treatment of rejection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed January 9, 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21745374">
<a name="21745374"></a>El-Bayoumi MA, El-Refaey AM, Abdelkader AM, El-Assmy MM, Alwakeel AA, El-Tahan HM. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study. <i>Crit Care</i>. 2011;15(4):R164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/21745374/pubmed" id="21745374" target="_blank">21745374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18796075">
<a name="18796075"></a>Elovaara I, Apostolski S, van Doorn P, et al; EFNS. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS Task Force on the Use of Intravenous Immunoglobulin in Treatment of Neurological Diseases. <i>Eur J Neurol</i>. 2008;15(9):893-908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/18796075/pubmed" id="18796075" target="_blank">18796075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15680069">
<a name="15680069"></a>English RF, Janosky JE, Ettedgui JA, et al, "Outcomes for Children With Acute Myocarditis," <i>Cardiol Young</i>, 2004, 14(5):488-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/15680069/pubmed" id="15680069" target="_blank">15680069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>FDA Safety Communication: updated information on the risks of thrombosis and hemolysis potentially related to administration of intravenous, subcutaneous and intramuscular human immune globulin products. November, 13, 2012. <a href="http://wayback.archive-it.org/7993/20170112095655/http:/www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm327934.htm" target="_blank">http://wayback.archive-it.org/7993/20170112095655/http:/www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm327934.htm</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17397768">
<a name="17397768"></a>Feasby T, Banwell B, Benstead T, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. <i>Transfus Med Rev.</i> 2007;21(2)(suppl 1):57-107. doi:10.1016/j.tmrv.2007.01.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/17397768/pubmed" id="17397768" target="_blank">17397768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23744661">
<a name="23744661"></a>Flebogamma 5% DIF (immune globulin intravenous [human]) [prescribing information]. Barcelona, Spain: Instituto Grifols, SA; September 2019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/23744661/pubmed" id="23744661" target="_blank">23744661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Instituto.1">
<a name="Instituto.1"></a>Flebogamma 10% DIF (immune globulin intravenous [human]) [prescribing information]. Barcelona, Spain: Instituto Grifols; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2173460">
<a name="2173460"></a>Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. <i>Ann Intern Med.</i> 1990;113(12):926-933. doi:10.7326/0003-4819-113-12-926<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/2173460/pubmed" id="2173460" target="_blank">2173460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34340891">
<a name="34340891"></a>Fu HY, Wang YC, Tsao CI, et al. Outcome of urgent desensitization in sensitized heart transplant recipients. <i>J Formos Med Assoc</i>. 2022;121(5):969-977. doi:10.1016/j.jfma.2021.07.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/34340891/pubmed" id="34340891" target="_blank">34340891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16286541">
<a name="16286541"></a>Gajdos P, Tranchant C, Clair B, et al; Myasthenia Gravis Clinical Study Group. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. <i>Arch Neurol</i>. 2005;62(11):1689-1693. doi:10.1001/archneur.62.11.1689<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/16286541/pubmed" id="16286541" target="_blank">16286541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2901668">
<a name="2901668"></a>Gale RP, Chapel HM, Bunch C, et al; Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. <i>N Engl J Med.</i> 1988;319(14):902-907. doi:10.1056/NEJM198810063191403<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/2901668/pubmed" id="2901668" target="_blank">2901668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GamaSTAN.2018.02">
<a name="GamaSTAN.2018.02"></a>GamaSTAN (immune globulin intramuscular [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics LLC; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GamaSTANSD.2017.06">
<a name="GamaSTANSD.2017.06"></a>GamaSTAN S/D (immune globulin intramuscular [human]) [product monograph]. Mississauga, Ontario, Canada: Grifols Therapeutics Inc; February 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gammagard.2020.11">
<a name="Gammagard.2020.11"></a>Gammagard Liquid (immune globulin intravenous and subcutaneous [human]) [prescribing information]. Lexington, MA: Baxalta US Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GammagardSD.2020.11">
<a name="GammagardSD.2020.11"></a>Gammagard S/D (immune globulin intravenous [human]) [prescribing information]. Lexington, MA: Baxalta US Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GammagardSD.2016.12">
<a name="GammagardSD.2016.12"></a>Gammagard S/D (immune globulin intravenous [human]) [product monograph]. Mississauga, Ontario: Baxalta Canada Corporation; December 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gammaked.2018.06">
<a name="Gammaked.2018.06"></a>Gammaked (immune globulin intravenous and subcutaneous [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics LLC; January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BPL.1">
<a name="BPL.1"></a>Gammaplex 5% (immune globulin intravenous [human]) [prescribing information]. Durham, NC: BPL Inc; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BPL.2">
<a name="BPL.2"></a>Gammaplex 10% (immune globulin intravenous [human]) [prescribing information]. Durham, NC: BPL Inc; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Grifols.2">
<a name="Grifols.2"></a>Gamunex-C (immune globulin [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics LLC; January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Grifols.3">
<a name="Grifols.3"></a>Gamunex-C (immune globulin [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics LLC; June 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26843919">
<a name="26843919"></a>Garcia-Roca R, Tzvetanov IG, Jeon H, Hetterman E, Oberholzer J, Benedetti E. Successful living donor intestinal transplantation in cross-match positive recipients: initial experience. <i>World J Gastrointest Surg</i>. 2016;8(1):101-105. doi:10.4240/wjgs.v8.i1.101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/26843919/pubmed" id="26843919" target="_blank">26843919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24279605">
<a name="24279605"></a>Gerlach UA, Lachmann N, Sawitzki B, et al. Clinical relevance of the de novo production of anti-HLA antibodies following intestinal and multivisceral transplantation. <i>Transpl Int</i>. 2014;27(3):280-289. doi:10.1111/tri.12250<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/24279605/pubmed" id="24279605" target="_blank">24279605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-217893">
<a name="217893"></a>Gershon AA, Piomelli S, Karpatkin M, Smithwick E, Steinberg S. Antibody to varicella-zoster virus after passive immunization against chickenpox. <i>J Clin Microbiol</i>. 1978;8(6):733-735.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/217893/pubmed" id="217893" target="_blank">217893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18723908">
<a name="18723908"></a>Girish G, Chawla D, Agarwal R, et al, "Efficacy of Two Dose Regimes of Intravenous Immunoglobulin in Rh Hemolytic Disease of Newborn--a Randomized Controlled Trial," <i>Indian Pediatr</i>, 2008, 45(8):653-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/18723908/pubmed" id="18723908" target="_blank">18723908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12243496">
<a name="12243496"></a>Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). <i>Am J Transplant</i>. 2002;2(8):758-760. doi:10.1034/j.1600-6143.2002.20809.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/12243496/pubmed" id="12243496" target="_blank">12243496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16794543">
<a name="16794543"></a>Gondolesi G, Blondeau B, Maurette R, et al. Pretransplant immunomodulation of highly sensitized small bowel transplant candidates with intravenous immune globulin. <i>Transplantation</i>. 2006;81(12):1743-1746. doi:10.1097/01.tp.0000226078.94635.76<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/16794543/pubmed" id="16794543" target="_blank">16794543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35257507">
<a name="35257507"></a>Gorelik M, Chung SA, Ardalan K, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of Kawasaki disease. <i>Arthritis Care Res (Hoboken)</i>. 2022;74(4):538-548. doi:10.1002/acr.24838<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/35257507/pubmed" id="35257507" target="_blank">35257507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1546732">
<a name="1546732"></a>Gottlieb F, Deutsch J. Red cell aplasia responsive to immunoglobulin therapy as initial manifestation of human immunodeficiency virus infection. <i>Am J Med.</i> 1992;92(3):331-333. doi:10.1016/0002-9343(92)90085-p<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/1546732/pubmed" id="1546732" target="_blank">1546732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12496219">
<a name="12496219"></a>Gottstein R, Cooke RW. Systematic Review of Intravenous Immunoglobulin in Haemolytic Disease of the Newborn. <i>Arch Dis Child Fetal Neonatal Ed.</i> 2003;88(1):F6-F10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/12496219/pubmed" id="12496219" target="_blank">12496219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31578070">
<a name="31578070"></a>Grindeland JW, Grindeland CJ, Moen C, Leedahl ND, Leedahl DD. Outcomes associated with standardized ideal body weight dosing of intravenous immune globulin in hospitalized patients: a multicenter study. <i>Ann Pharmacother</i>. 2020;54(3):205-212. doi:10.1177/1060028019880300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/31578070/pubmed" id="31578070" target="_blank">31578070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33175401">
<a name="33175401"></a>Guihaire J, D'Avino S, Stephan F, et al. Urgent desensitization in patients bridged to heart transplantation under extracorporeal membrane oxygenation support: a preliminary experience. <i>Clin Transplant</i>. 2021;35(1):e14146. doi:10.1111/ctr.14146<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/33175401/pubmed" id="33175401" target="_blank">33175401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29951056">
<a name="29951056"></a>Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. <i>Front Immunol</i>. 2018;9:1299. doi:10.3389/fimmu.2018.01299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/29951056/pubmed" id="29951056" target="_blank">29951056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20558084">
<a name="20558084"></a>Hachem RR, Yusen RD, Meyers BF, et al. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. <i>J Heart Lung Transplant</i>. 2010;29(9):973-980. doi:10.1016/j.healun.2010.05.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/20558084/pubmed" id="20558084" target="_blank">20558084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8813271">
<a name="8813271"></a>Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. <i>Brain</i>. 1996;119(pt 4):1067-1077. doi:10.1093/brain/119.4.1067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/8813271/pubmed" id="8813271" target="_blank">8813271</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29540348">
<a name="29540348"></a>Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. <i>Blood</i>. 2018;131(25):2745-2760. doi:10.1182/blood-2017-09-806398<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/29540348/pubmed" id="29540348" target="_blank">29540348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35118829">
<a name="35118829"></a>Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology (ACR) clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: Version 3. <i>Arthritis Rheumatol</i>. Published online February 3, 2022. doi:10.1002/art.42062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/35118829/pubmed" id="35118829" target="_blank">35118829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15040478">
<a name="15040478"></a>Herzog S, Schmidt E, Goebeler M, Bröcker EB, Zillikens D. Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins.<i> Acta Derm Venereol.</i> 2004;84(1):48-52. doi:10.1080/00015550310005861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/15040478/pubmed" id="15040478" target="_blank">15040478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2016">
<a name="HHS.2016"></a>HHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. December 2016. <a href="https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf" target="_blank">https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15155409">
<a name="15155409"></a>Hia CP, Yip WC, Tai BC, et al, "Immunosuppressive Therapy in Acute Myocarditis: An 18 Year Systematic Review," <i>Arch Dis Child</i>, 2004, 89(6):580-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/15155409/pubmed" id="15155409" target="_blank">15155409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CSL.1">
<a name="CSL.1"></a>Hizentra (immune globulin) [prescribing information]. Kankakee, IL: CSL Behring LLC; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CSL.2">
<a name="CSL.2"></a>Hizentra (immune globulin) [product monograph]. Ottawa, Ontario, Canada: CSL Behring Canada Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28263379">
<a name="28263379"></a>Hodkinson JP. Considerations for dosing immunoglobulin in obese patients. <i>Clin Exp Immunol</i>. 2017;188(3):353-362. doi:10.1111/cei.12955<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/28263379/pubmed" id="28263379" target="_blank">28263379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25731216">
<a name="25731216"></a>Hodkinson JP, Lucas M, Lee M, Harrison M, Lunn MP, Chapel H. Therapeutic immunoglobulin should be dosed by clinical outcome rather than by body weight in obese patients. <i>Clin Exp Immunol</i>. 2015;181(1):179-187. doi:10.1111/cei.12616<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/25731216/pubmed" id="25731216" target="_blank">25731216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18178525">
<a name="18178525"></a>Hughes RA, Donofrio P, Bril V, et al; ICE Study Group. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. <i>Lancet Neurol.</i> 2008;7(2):136-144. doi:10.1016/S1474-4422(07)70329-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/18178525/pubmed" id="18178525" target="_blank">18178525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baxalta.1">
<a name="Baxalta.1"></a>HyQvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21962214">
<a name="21962214"></a>INIS Collaborative Group, Brocklehurst P, Farrell B, et al, "Treatment of Neonatal Sepsis With Intravenous Immune Globulin," <i>N Engl J Med</i>, 2011, 365(13):1201-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/21962214/pubmed" id="21962214" target="_blank">21962214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2901668">
<a name="2901668"></a>Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia (CGSIGCLL). <i>N Engl J Med</i>. 1988;319(14):902-907.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/2901668/pubmed" id="2901668" target="_blank">2901668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34498551">
<a name="34498551"></a>Ishida H, Unagami K, Omoto K, Kanzawa T, Tanabe K. Desensitization regimen consisting of high-dose intravenous immunoglobulin, plasmapheresis, and rituximab (an anti-CD20 antibody), without eculizumab and/or bortezomib, in 41 highly sensitized kidney transplant recipients. <i>Exp Clin Transplant</i>. 2021;19(10):1032-1040. doi:10.6002/ect.2021.0234<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/34498551/pubmed" id="34498551" target="_blank">34498551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9099759">
<a name="9099759"></a>Jenson HB and Pollock BH, "Meta-Analyses of the Effectiveness of Intravenous Immune Globulin for Prevention and Treatment of Neonatal Sepsis," <i>Pediatrics</i>, 1997, 99(2):E2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/9099759/pubmed" id="9099759" target="_blank">9099759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36675702">
<a name="36675702"></a>Jiang H, Guo H, Yang B, et al. Acute antibody-mediated rejection in liver transplant recipients with autoimmune liver disease: a clinical and pathologic study of 4 cases. <i>J Pers Med</i>. 2022;13(1):41. doi:10.3390/jpm13010041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/36675702/pubmed" id="36675702" target="_blank">36675702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10567309">
<a name="10567309"></a>John R, Lietz K, Burke E, et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. <i>Circulation</i>. 1999;100(19 suppl):II229-11235. doi:10.1161/01.cir.100.suppl_2.ii-229<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/10567309/pubmed" id="10567309" target="_blank">10567309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11250390">
<a name="11250390"></a>John R, Lietz K, Burke E, et al. Intravenous immunoglobulin therapy in highly sensitized cardiac allograft recipients facilitates transplantation across donor specific IgG positive cross matches. <i>J Heart Lung Transplant</i>. 2001;20(2):213. doi:10.1016/s1053-2498(00)00463-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/11250390/pubmed" id="11250390" target="_blank">11250390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32830877">
<a name="32830877"></a>Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology (EADV). <i>J Eur Acad Dermatol Venereol</i>. 2020;34(9):1900-1913. doi:10.1111/jdv.16752<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/32830877/pubmed" id="32830877" target="_blank">32830877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jordan.1">
<a name="Jordan.1"></a>Jordan JA. Treatment and prevention of parvovirus B19 infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed June 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15579530">
<a name="15579530"></a>Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. <i>J Am Soc Nephrol</i>. 2004;15(12):3256-3262. doi:10.1097/01.ASN.0000145878.92906.9F<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/15579530/pubmed" id="15579530" target="_blank">15579530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12973100">
<a name="12973100"></a>Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. <i>Transplantation</i>. 2003;76(4):631-636. doi:10.1097/01.TP.0000080685.31697.FC<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/12973100/pubmed" id="12973100" target="_blank">12973100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19845597">
<a name="19845597"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. <i>Am J Transplant.</i> 2009;9(suppl 3):S1-S155. doi:10.1111/j.1600-6143.2009.02834.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/19845597/pubmed" id="19845597" target="_blank">19845597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19936586">
<a name="19936586"></a>Klugman D, Berger JT, Sable CA, et al, "Pediatric Patients Hospitalized With Myocarditis: A Multi-institutional Analysis," <i>Pediatr Cardiol</i>, 2010, 31(2):222-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/19936586/pubmed" id="19936586" target="_blank">19936586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19285611">
<a name="19285611"></a>Kobashigawa J, Mehra M, West L, et al; Consensus Conference Participants. Report from a consensus conference on the sensitized patient awaiting heart transplantation. <i>J Heart Lung Transplant</i>. 2009;28(3):213-225. doi:10.1016/j.healun.2008.12.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/19285611/pubmed" id="19285611" target="_blank">19285611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29452978">
<a name="29452978"></a>Kobashigawa J, Colvin M, Potena L, et al. The management of antibodies in heart transplantation: an ISHLT consensus document. <i>J Heart Lung Transplant</i>. 2018;37(5):537-547. doi:10.1016/j.healun.2018.01.1291<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/29452978/pubmed" id="29452978" target="_blank">29452978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20973825">
<a name="20973825"></a>Kobashigawa JA, Patel JK, Kittleson MM, et al. The long-term outcome of treated sensitized patients who undergo heart transplantation. <i>Clin Transplant</i>. 2011;25(1):E61-E67. doi:10.1111/j.1399-0012.2010.01334.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/20973825/pubmed" id="20973825" target="_blank">20973825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23485027">
<a name="23485027"></a>Kobayashi T, Kobayashi T, Morikawa A, et al. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease. <i>J Pediatr</i>. 2013;163(2):521-526. doi:10.1016/j.jpeds.2013.01.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/23485027/pubmed" id="23485027" target="_blank">23485027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12240888">
<a name="12240888"></a>Koduri PR. Parvovirus B19-related anemia in HIV-infected patients. <i>AIDS Patient Care STDS</i>. 2000;14(1):7-11. doi:10.1089/108729100318082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/12240888/pubmed" id="12240888" target="_blank">12240888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10331506">
<a name="10331506"></a>Koduri PR, Kumapley R, Valladares J, Teter C. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin--a report of eight patients. <i>Am J Hematol.</i> 1999;61(1):16-20. doi:10.1002/(sici)1096-8652(199905)61:1&lt;16::aid-ajh4&gt;3.0.co;2-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/10331506/pubmed" id="10331506" target="_blank">10331506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19811851">
<a name="19811851"></a>Koh MJ and Tay YK, "Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Asian Children," <i>J Am Acad Dermatol</i>, 2010, 62(1):54-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/19811851/pubmed" id="19811851" target="_blank">19811851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15995024">
<a name="15995024"></a>Korinthenberg R, Schessl J, Kirschner J, Mönting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. <i>Pediatrics</i>. 2005;116(1):8-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/15995024/pubmed" id="15995024" target="_blank">15995024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31890472">
<a name="31890472"></a>Lachiewicz AM, Srinivas ML. Varicella-zoster virus post-exposure management and prophylaxis: a review.<i> Prev Med Rep.</i> 2019;16:101016. doi:10.1016/j.pmedr.2019.101016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/31890472/pubmed" id="31890472" target="_blank">31890472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25583939">
<a name="25583939"></a>Lagasse C, Hatton RC, Pyles E. A survey of intravenous immune globulin (IVIG) dosing strategies. <i>Ann Pharmacother</i>. 2015;49(2):254-257. doi:10.1177/1060028014559095<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/25583939/pubmed" id="25583939" target="_blank">25583939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lange.1">
<a name="Lange.1"></a>Lange DJ, Robison-Papp J. Multifocal motor neuropathy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed January 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28495807">
<a name="28495807"></a>Larkin J, Chmielowski B, Lao CD, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. <i>Oncologist</i>. 2017;22(6):709-718. doi:10.1634/theoncologist.2016-0487<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/28495807/pubmed" id="28495807" target="_blank">28495807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1901084">
<a name="1901084"></a>Leung DY, Kelly CP, Boguniewicz M, et al, "Treatment With Intravenously Administered Gamma Globulin of Chronic Relapsing Colitis Induced by <i>Clostridium difficile</i> Toxin," <i>J Pediatr</i>, 1991, 118(4 Pt 1):633-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/1901084/pubmed" id="1901084" target="_blank">1901084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lewis.1">
<a name="Lewis.1"></a>Lewis RA, Ashok Muley S. Chronic inflammatory demyelinating polyneuropathy: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed February 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36033645">
<a name="36033645"></a>Mamode N, Bestard O, Claas F, Furian L, Griffin S, Legendre C, Pengel L, Naesens M. European guideline for the management of kidney transplant patients with HLA antibodies: by the European Society for Organ Transplantation Working Group. <i>Transpl Int</i>. 2022;35:10511. doi:10.3389/ti.2022.10511<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/36033645/pubmed" id="36033645" target="_blank">36033645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11954856">
<a name="11954856"></a>Marchioni E, Marinou-Aktipi K, Uggetti C, et al. Effectiveness of intravenous immunoglobulin treatment in adult patients with steroid-resistant monophasic or recurrent acute disseminated encephalomyelitis. <i>J Neurol.</i> 2002;249(1):100-104. doi:10.1007/pl00007836<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/11954856/pubmed" id="11954856" target="_blank">11954856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17585291">
<a name="17585291"></a>Marin M, Güris D, Chaves SS, Schmid S, Seward JF; Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep.</i> 2007;56(RR-4):1-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/17585291/pubmed" id="17585291" target="_blank">17585291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30887675">
<a name="30887675"></a>Marks WH, Mamode N, Montgomery RA, et al; C10-001 Study Group. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial. <i>Am J Transplant</i>. 2019;19(10):2876-2888. doi:10.1111/ajt.15364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/30887675/pubmed" id="30887675" target="_blank">30887675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28356445">
<a name="28356445"></a>McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki Disease: a scientific statement for health professionals from the American Heart Association. <i>Circulation</i>. 2017;135(17):e927-e999. doi: 10.1161/CIR.0000000000000484.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/28356445/pubmed" id="28356445" target="_blank">28356445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10997362">
<a name="10997362"></a>McFarland LV, Brandmarker SA, and Guandalini S, "Pediatric <i>Clostridium difficile</i>: A Phantom Menace or Clinical Reality?" <i>J Pediatr Gastroenterol Nutr</i>, 2000, 31(3):220-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/10997362/pubmed" id="10997362" target="_blank">10997362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23760231">
<a name="23760231"></a>McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS; Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2013;62(RR-04):1-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/23760231/pubmed" id="23760231" target="_blank">23760231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11222785">
<a name="11222785"></a>Mendell JR, Barohn RJ, Freimer ML, et al; Working Group on Peripheral Neuropathy. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. <i>Neurology</i>. 2001;56(4):445-449. doi:10.1212/wnl.56.4.445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/11222785/pubmed" id="11222785" target="_blank">11222785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15590442">
<a name="15590442"></a>Miqdad AM, Abdelbasit OB, Shaheed MM, et al, "Intravenous Immunoglobulin G (IVIG) Therapy for Significant Hyperbilirubinemia in ABO Hemolytic Disease of the Newborn," <i>J Matern Fetal Neonatal Med</i>, 2004, 16(3):163-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/15590442/pubmed" id="15590442" target="_blank">15590442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21793744">
<a name="21793744"></a>Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. <i>N Engl J Med</i>. 2011;365(4):318-326. doi:10.1056/NEJMoa1012376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/21793744/pubmed" id="21793744" target="_blank">21793744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11036849">
<a name="11036849"></a>Morici MV, Galen WK, Shetty AK, et al, "Intravenous Immunoglobulin Therapy for Children With Stevens-Johnson Syndrome," <i>J Rheumatol</i>, 2000, 27(10):2494-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/11036849/pubmed" id="11036849" target="_blank">11036849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Morrison.1">
<a name="Morrison.1"></a>Morrison VA. Prevention of infections in patients with chronic lymphocytic leukemia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed May 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9149073">
<a name="9149073"></a>Muchnik S, Losavio AS, Vidal A, Cura L, Mazia C. Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin. <i>Muscle Nerve.</i> 1997;20(6):674-678. doi:10.1002/(sici)1097-4598(199706)20:6&lt;674::aid-mus3&gt;3.0.co;2-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/9149073/pubmed" id="9149073" target="_blank">9149073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Muley.1">
<a name="Muley.1"></a>Muley SA. Guillain-Barré syndrome in adults: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed October 7, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29438767">
<a name="29438767"></a>Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts. <i>J Am Acad Dermatol</i>. 2020;82(3):575-585.e1. doi:10.1016/j.jaad.2018.02.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/29438767/pubmed" id="29438767" target="_blank">29438767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Therapeutic management of hospitalized pediatric patients with multisystem inflammatory syndrome in children (MIS-C) (with discussion on multisystem inflammatory syndrome in adults [MIS-A]). <a href="https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-pediatric-patients--therapeutic-management-of-mis-c/" target="_blank">https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-pediatric-patients--therapeutic-management-of-mis-c/</a>. Updated February 24, 2022. Accessed March 7, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32614811">
<a name="32614811"></a>Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of hepatitis A virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices, 2020. <i>MMWR Recomm Rep</i>. 2020;69(5):1-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/32614811/pubmed" id="32614811" target="_blank">32614811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21325604">
<a name="21325604"></a>Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. <i>Blood</i>. 2011;117(16):4190-4207. doi:10.1182/blood-2010-08-302984<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/21325604/pubmed" id="21325604" target="_blank">21325604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31794604">
<a name="31794604"></a>Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia.<i> Blood Adv.</i> 2019;3(23):3829-3866. doi:10.1182/bloodadvances.2019000966<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/31794604/pubmed" id="31794604" target="_blank">31794604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1709446">
<a name="1709446"></a>Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. <i>N Engl J Med</i>. 1991;324(23):1633-1639. doi:10.1056/NEJM199106063242305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/1709446/pubmed" id="1709446" target="_blank">1709446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16791398">
<a name="16791398"></a>Nguyen MK, Rastogi A, Kurtz I. True hyponatremia secondary to intravenous immunoglobulin. <i>Clin Exp Nephrol</i>. 2006;10(2):124-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/16791398/pubmed" id="16791398" target="_blank">16791398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34431797">
<a name="34431797"></a>Nguyen TP, Nguyen TD, Zhu L, et al. Precision intravenous immunoglobulin dosing and clinical outcomes: a retrospective chart review. <i>J Clin Neuromuscul Dis</i>. 2021;23(1):18-23. doi:10.1097/CND.0000000000000359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/34431797/pubmed" id="34431797" target="_blank">34431797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2255028">
<a name="2255028"></a>NIH Consensus Conference. Intravenous immunoglobulin. Prevention and treatment of disease. <i>JAM</i>A. 1990;264(24):3189-3193.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/2255028/pubmed" id="2255028" target="_blank">2255028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Octapharma.2">
<a name="Octapharma.2"></a>Octagam (immune globulin intravenous [human]) [prescribing information]. Hoboken, NJ: Octapharma USA Inc; October 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Octapharma.7">
<a name="Octapharma.7"></a>Octagam 5% (immune globulin intravenous [human]) [prescribing information]. New York, NY: Pfizer Labs; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Octapharma.3">
<a name="Octapharma.3"></a>Octagam 5% (immune globulin intravenous [human]) [prescribing information]. Paramus, NJ: Octapharma USA Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Octapharma.4">
<a name="Octapharma.4"></a>Octagam 5% (immune globulin intravenous [human]) [product monograph]. Toronto, Canada: Octapharma Canada Inc; November 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Octapharma.5">
<a name="Octapharma.5"></a>Octagam 10% (immune globulin intravenous [human]) [prescribing information]. Paramus, NJ: Octapharma USA Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Octapharma.6">
<a name="Octapharma.6"></a>Octagam 10% (immune globulin intravenous [human]) [product monograph]. Toronto, Ontario, Canada: Octapharma Canada Inc; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20238315">
<a name="20238315"></a>Ohlsson A and Lacy J, "Intravenous Immunoglobulin for Suspected or Subsequently Proven Infection in Neonates," <i>Cochrane Database Syst Rev</i>, 2010, (3):CD001239.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/20238315/pubmed" id="20238315" target="_blank">20238315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Orange.1">
<a name="Orange.1"></a>Orange JS. Immune globulin therapy in primary immunodeficiency. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed August 17, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22015886">
<a name="22015886"></a>Pacheco LD, Berkowitz RL, Moise KJ Jr, Bussel JB, McFarland JG, Saade GR. Fetal and neonatal alloimmune thrombocytopenia: a management algorithm based on risk stratification. <i>Obstet Gynecol</i>. 2011;118(5):1157-1163. doi:10.1097/AOG.0b013e31823403f4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/22015886/pubmed" id="22015886" target="_blank">22015886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi: 10.1155/2012/985646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Paramus.1">
<a name="Paramus.1"></a>Panzyga (immune globulin intravenous [human] - ifas) [prescribing information]. Paramus, NJ: Octapharma USA Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29994978">
<a name="29994978"></a>Parajuli S, Alagusundaramoorthy S, Aziz F, et al. Outcomes of pancreas transplant recipients with de novo donor-specific antibodies. <i>Transplantation</i>. 2019;103(2):435-440. doi:10.1097/TP.0000000000002339<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/29994978/pubmed" id="29994978" target="_blank">29994978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Parajuli.1">
<a name="Parajuli.1"></a>Parajuli S, Brennan DC. Kidney transplantation in adults: prevention and treatment of antibody-mediated rejection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed January 9, 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29788397">
<a name="29788397"></a>Parks T, Wilson C, Curtis N, Norrby-Teglund A, Sriskandan S. Polyspecific intravenous immunoglobulin in clindamycin-treated patients with streptococcal toxic shock syndrome: a systematic review and meta-analysis. <i>Clin Infect Dis</i>. 2018;67(9):1434-1436. doi:10.1093/cid/ciy401<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/29788397/pubmed" id="29788397" target="_blank">29788397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22454268">
<a name="22454268"></a>Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2012;78(13):1009-1015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/22454268/pubmed" id="22454268" target="_blank">22454268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32036588">
<a name="32036588"></a>Pecoraro A, Ricci S, Vultaggio A, Boggia GM, Spadaro G; SHIFT and IBIS Study Groups. Correlations among subcutaneous immunoglobulin dosage, immunoglobulin G serum pre-infusional levels and body mass index in primary antibody deficiency patients: a pooled analysis from the SHIFT/IBIS studies. <i>Clin Drug Investig</i>. 2020;40(3):279-286. doi:10.1007/s40261-020-00885-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/32036588/pubmed" id="32036588" target="_blank">32036588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi: 10.1002/bdrb.20201.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28041678">
<a name="28041678"></a>Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. <i>J Allergy Clin Immunol.</i> 2017;139(3S):S1-S46. doi:10.1016/j.jaci.2016.09.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/28041678/pubmed" id="28041678" target="_blank">28041678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9014908">
<a name="9014908"></a>Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. <i>Lancet</i>. 1997;349(9047):225-230.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/9014908/pubmed" id="9014908" target="_blank">9014908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33521247">
<a name="33521247"></a>Plazak ME, Gale SE, Reed BN, et al. Clinical outcomes of perioperative desensitization in heart transplant recipients. <i>Transplant Direct</i>. 2021;7(2):e658. doi:10.1097/TXD.0000000000001111<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/33521247/pubmed" id="33521247" target="_blank">33521247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CSL.2">
<a name="CSL.2"></a>Privigen (immune globulin intravenous [human]) [prescribing information]. Kankakee, IL: CSL Behring LLC; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11459901">
<a name="11459901"></a>Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC; French Guillain-Barré Syndrome Cooperative Group. Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days. <i>J Neurol Neurosurg Psychiatry</i>. 2001;71(2):235-238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/11459901/pubmed" id="11459901" target="_blank">11459901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9140371">
<a name="9140371"></a>Rich MM, Teener JW, Bird SJ. Treatment of Lambert-Eaton syndrome with intravenous immunoglobulin. <i>Muscle Nerve.</i> 1997;20(5):614-615. doi:10.1002/(sici)1097-4598(199705)20:5&lt;614::aid-mus13&gt;3.0.co;2-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/9140371/pubmed" id="9140371" target="_blank">9140371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35126855">
<a name="35126855"></a>Robinson TJ, Hendele JB, Gimferrer I, et al. Acute liver failure secondary to acute antibody mediated rejection after compatible liver transplant: a case report. <i>World J Hepatol</i>. 2022;14(1):287-294. doi:10.4254/wjh.v14.i1.287<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/35126855/pubmed" id="35126855" target="_blank">35126855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34281777">
<a name="34281777"></a>Saadi TA, Lawrecki T, Narang N, et al. Outcomes of pre- heart transplantation desensitization in a series of highly sensitized patients bridged with left ventricular assist devices. <i>J Heart Lung Transplant</i>. 2021;40(10):1107-1111. doi:10.1016/j.healun.2021.05.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/34281777/pubmed" id="34281777" target="_blank">34281777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27358333">
<a name="27358333"></a>Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. <i>Neurology</i>. 2016;87(4):419-425. doi: 10.1212/WNL.0000000000002790.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/27358333/pubmed" id="27358333" target="_blank">27358333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31170898">
<a name="31170898"></a>Santeusanio AD, Moon J, Nair V, Iyer KR. Is there a role for desensitization in intestinal transplantation? <i>Prog Transplant</i>. 2019;29(3):275-278. doi:10.1177/1526924819855088<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/31170898/pubmed" id="31170898" target="_blank">31170898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26555944">
<a name="26555944"></a>Sautenet B, Blancho G, Büchler M, et al. One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial. <i>Transplantation</i>. 2016;100(2):391-399. doi:10.1097/TP.0000000000000958<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/26555944/pubmed" id="26555944" target="_blank">26555944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34724392">
<a name="34724392"></a>Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/34724392/pubmed" id="34724392" target="_blank">34724392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Siegel.1">
<a name="Siegel.1"></a>Siegel J. Immune globulins: therapeutic, pharmaceutical, cost and administration considerations. <i>Pharmacy Practice News.</i> 2011;20-27.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Siegel.2">
<a name="Siegel.2"></a>Siegel J. Immunoglobulins and obesity. <i>Pharmacy Practice News.</i> 2010;37:1.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20402760">
<a name="20402760"></a>Skeie GO, Apostolski S, Evoli A, et al; European Federation of Neurological Societies. Guidelines for treatment of autoimmune neuromuscular transmission disorders. <i>Eur J Neurol</i>. 2010;17(7):893-902.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/20402760/pubmed" id="20402760" target="_blank">20402760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35426974">
<a name="35426974"></a>Sommer W, Avsar M, Aburahma K, et al. Heart transplantation across preformed donor-specific antibody barriers using a perioperative desensitization protocol. <i>Am J Transplant</i>. 2022;22(8):2064-2076. doi:10.1111/ajt.17060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/35426974/pubmed" id="35426974" target="_blank">35426974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12749010">
<a name="12749010"></a>Steinberger BA, Ford SM, Coleman TA. Intravenous immunoglobulin therapy results in post-infusional hyperproteinemia, increased serum viscosity, and pseudohyponatremia. <i>Am J Hematol</i>. 2003;73(2):97-100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/12749010/pubmed" id="12749010" target="_blank">12749010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29028117">
<a name="29028117"></a>Stump SE, Schepers AJ, Jones AR, Alexander MD, Auten JJ. Comparison of weight-based dosing strategies for intravenous immunoglobulin in patients with hematologic malignancies. <i>Pharmacotherapy</i>. 2017;37(12):1530-1536. doi:10.1002/phar.2047<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/29028117/pubmed" id="29028117" target="_blank">29028117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33876782">
<a name="33876782"></a>Sugunan S, Bindusha S, Geetha S, Niyas HR, Kumar AS. Clinical profile and short-term outcome of children with SARS-CoV-2 related multisystem inflammatory syndrome (MIS-C) treated with pulse methylprednisolone. <i>Indian Pediatr</i>. 2021;58(8):718-722. doi:10.1007/s13312-021-2277-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/33876782/pubmed" id="33876782" target="_blank">33876782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15196059">
<a name="15196059"></a>Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. <i>Am J Transplant</i>. 2004;4(7):1033-1041. doi:10.1111/j.1600-6143.2004.00500.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/15196059/pubmed" id="15196059" target="_blank">15196059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Targoff.1">
<a name="Targoff.1"></a>Targoff IN. Treatment of recurrent and resistant dermatomyositis and polymyositis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed March 1, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19747629">
<a name="19747629"></a>Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238. doi:10.1016/j.bbmt.2009.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/19747629/pubmed" id="19747629" target="_blank">19747629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12271299">
<a name="12271299"></a>Tristani-Firouzi P, Petersen MJ, Saffle JR, et al, "Treatment of Toxic Epidermal Necrolysis With Intravenous Immunoglobulin in Children," <i>J Am Acad Dermatol</i>, 2002, 47(4):548-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/12271299/pubmed" id="12271299" target="_blank">12271299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32492226">
<a name="32492226"></a>Uva PD, Quevedo A, Roses J, et al. Anti-HLA donor-specific antibody monitoring in pancreas transplantation: role of protocol biopsies. <i>Clin Transplant</i>. 2020;34(8):e13998. doi:10.1111/ctr.13998<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/32492226/pubmed" id="32492226" target="_blank">32492226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29122523">
<a name="29122523"></a>van Schaik IN, Bril V, van Geloven N, et al; PATH study group. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurol.</i> 2018;17(1):35-46. doi:10.1016/S1474-4422(17)30378-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/29122523/pubmed" id="29122523" target="_blank">29122523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21199100">
<a name="21199100"></a>van Schaik IN, Léger JM, Nobile-Orazio E, et al; Joint task force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first revision. <i>J Peripher Nerv Syst.</i> 2010;15(4):295-301. doi:10.1111/j.1529-8027.2010.00290.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/21199100/pubmed" id="21199100" target="_blank">21199100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37080658">
<a name="37080658"></a>Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. <i>J Heart Lung Transplant</i>. 2023;42(5):e1-e141. doi:10.1016/j.healun.2022.10.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/37080658/pubmed" id="37080658" target="_blank">37080658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vleugels.1">
<a name="Vleugels.1"></a>Vleugels RA. Management of refractory cutaneous dermatomyositis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed March 1, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17699296">
<a name="17699296"></a>Vo AA, Cam V, Toyoda M, Puliyanda DP, et al. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience. <i>Clin J Am Soc Nephrol</i>. 2006;1(4):844-852. doi:10.2215/CJN.01701105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/17699296/pubmed" id="17699296" target="_blank">17699296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18635429">
<a name="18635429"></a>Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. <i>N Engl J Med</i>. 2008;359(3):242-251. doi:10.1056/NEJMoa0707894<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/18635429/pubmed" id="18635429" target="_blank">18635429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20110854">
<a name="20110854"></a>Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. <i>Transplantation</i>. 2010;89(9):1095-1102. doi:10.1097/TP.0b013e3181d21e7f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/20110854/pubmed" id="20110854" target="_blank">20110854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Waldman.1">
<a name="Waldman.1"></a>Waldman AT. Acute disseminated encephalomyelitis (ADEM) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed March 29, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33743237">
<a name="33743237"></a>Walgaard C, Jacobs BC, Lingsma HF, et al; Dutch GBS Study Group. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial.<i> Lancet Neurol.</i> 2021;20(4):275-283. doi:10.1016/S1474-4422(20)30494-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/33743237/pubmed" id="33743237" target="_blank">33743237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28871852">
<a name="28871852"></a>Wasserman RL. Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases. <i>Immunotherapy</i>. 2017;9(12):1035-1050. doi:10.2217/imt-2017-0092<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/28871852/pubmed" id="28871852" target="_blank">28871852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9639369">
<a name="9639369"></a>Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 1998;47(RR-8):1-57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/9639369/pubmed" id="9639369" target="_blank">9639369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weinberg.1">
<a name="Weinberg.1"></a>Weinberg DH. Lambert-Eaton myasthenic syndrome: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed February 22, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wimperis.1">
<a name="Wimperis.1"></a>Wimperis J, Lunn M, Jones A, et al, National Health Service. Clinical Guidelines for the Use of Immunoglobulin Use: Second Edition Update, July 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wingard.1">
<a name="Wingard.1"></a>Wingard JR. Prevention of infections in hematopoietic cell transplant recipients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed June 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28130210">
<a name="28130210"></a>Winkelhorst D, Murphy MF, Greinacher A, et al. Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review. <i>Blood</i>. 2017;129(11):1538-1547. doi:10.1182/blood-2016-10-739656<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/28130210/pubmed" id="28130210" target="_blank">28130210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23953920">
<a name="23953920"></a>Witt CA, Gaut JP, Yusen RD, et al. Acute antibody-mediated rejection after lung transplantation. <i>J Heart Lung Transplant.</i> 2013;32(10):1034-1040. doi:10.1016/j.healun.2013.07.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/23953920/pubmed" id="23953920" target="_blank">23953920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435. Accessed April 17, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Grifols.1">
<a name="Grifols.1"></a>Xembify (immune globulin subcutaneous [human-klhw]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics LLC; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17353471">
<a name="17353471"></a>Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. <i>Neurology</i>. 2007;68(11):837-841.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/abstract-text/17353471/pubmed" id="17353471" target="_blank">17353471</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 83878 Version 436.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
